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Glossary 
 
Asymmetric unit.- The asymmetric unit of a space group is that part of the crystallo-
graphic unit cell which can be used to generate the complete unit cell by the symmetry 
of the space group. 
 
Miller indices.- A set of numbers that quantify the intercepts and thus may be used to 
uniquely identify the plane or surface in which the crystal is oriented. 
 
Crystal lattice.- Describes the periodicity of a crystal by mathematical points at specific 
coordinates in space.  
 
Reciprocal lattice.- There is a simple inverse relationship between the spacing of unit 
cells in the crystallographic real lattice and the spacing of reflections on the detector, 
which because of its inverse relationship to the real lattice, is called reciprocal. 
 
[Crystallographic] phase.- The Fourier transform of a function of time itself is a com-
plex-valued function of frequency, whose absolute value represents the amount of that 
frequency present in the original function, and whose complex argument is the phase 
offset of the basic sinusoid in that frequency. In crystallographic determination, each 
phase represents a characteristic arrangement of atoms.  
 
Collectins.- Soluble Ca2+-dependent (C-type) lectins with an N-terminal collagenous tri-
ple helical oligomerization domain. 
 
Epitope.- Also known as antigenic determinant, is the part of an antigen that is recog-
nized by the immune system, specifically by antibodies, B cells, or T cells. 
 
Glycocalyx.- A carbohydrate-enriched coating that covers the outside of many eukary-
otic cells and prokaryotic cells. 
 
Glycosidic linkage.- Linkage of a monosaccharide to another residue via the anomeric 
hydroxyl group. The linkage generally results from the reaction of a hemiacetal with an 
alcohol to form an acetal. Glycosidic linkage between two monosachharides have de-
fined regiochemistry and stereochemistry. 
 
Glycosidases.- An enzyme that catalyzes the hydrolysis of a bond joining a sugar of a 
glycoside to an alcohol or another sugar unit. 
 
Glycosyltransferases.- Enzymes involved in glycan biosynthesis and modification, in-
cluding aspects of substrate specificity, primary sequence relationships, structures and 
enzyme mechanisms. 
 
 
 
vii 
 
Great obstetrical syndromes.- refer to conditions with the following characteristics: 
(1) multiple etiologies; (2) a long preclinical period; (3) adaptive in nature; (4) fetal in-
volvement and (5) the result of complex interactions between the maternal and fetal ge-
nome and the environment. 
 
Hematopoiesis.- The formation of mature blood cellular components from stem cells 
and other undifferentiated blood cells. 
 
Integrins.- Heterodimeric transmembrane receptors that, upon ligand binding, activate 
signal transduction pathways that mediate cellular signals such as adhesion, regulation 
of the cell cycle, organization of the intracellular cytoskeleton, and movement of new 
receptors to the cell membrane. 
 
Jelly-roll.- This motif describes a particular topology for arranging antiparallel -strands 
in protein structures. 
 
Lectins.- Members of a superfamily of (glyco)proteins with the capacity to bind carbo-
hydrates which lack enzymatic activity and are distinct from antibodies and oligosac-
charide sensor/transport proteins. 
 
Monochromator.- An optical device that comprises a dispersive element, an entrance 
slit and mirrors to create a parallel beam similar to sunlight, and an exit slit and mirrors 
to extract the monochromatic (single-wavelength) light. 
 
Non-crystallographic symmetry.- A symmetry operation that is not compatible with 
the periodicity of a crystal pattern (in two or three dimensions). In biological crystallog-
raphy, the term 'non-crystallographic symmetry' is often used to indicate a symmetry 
relationship between similar subunits within the crystallographic asymmetric unit. This 
use comes from the fact that the operation required to superimpose one subunit on an-
other is similar to a space group operation, but it operates only over a local volume. 
 
Synchrotron radiation.- The name given to the radiation which occurs when charged 
particles are accelerated in a curved path or orbit. This radiated energy is proportional to 
the fourth power of the particle speed and is inversely proportional to the square. 
 
Unit cell.- Minimum volume cell corresponding to a single lattice point of a structure 
with discrete translational symmetry.
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ABSTRACT 
 
Galectins are a family of -galactoside-binding proteins located in a wide range of 
organisms, from mammals to fungi and prokaryotes, where they exert functions that 
can be mediated by both carbohydrate-protein or protein-protein interactions. Galec-
tins were classified based on their structural features in prototype, tandem-repeat and 
chimeric type. The prototype galectins contain a single CRD and can form homodi-
mers whereas the tandem-repeat galectins are formed by two non-identical CRDs. 
The chimeric galectins have a distinctive N-terminal domain comprised of a lead 
peptide and nine poly-Pro/Gly repeats (namely, N-PG) linked to the C-terminal 
CRD. In humans, the only chimeric type is Galectin-3 (Gal-3). The N-PG module 
had eluded structural resolution so far, albeit the many reports on the CRD structure. 
Using a protein engineering approach, Gal-3 constructs with different lengths of the 
N-PG were produced and set to crystallize. A particular construct, with repeats VII 
to IX and the lead domain (Gal-3[N VII-IX]) crystallized with high-reproducibility. 
The crystals belonged to the orthorhombic space group P212121 and had a resolution 
of 2.2 Å. Further studies were performed in this construct and the full-length protein 
by Small-Angle X-ray Scattering. Taken together, the results on the structural char-
acterization of Gal-3[N VII-IX] allow to ascertain the position of key amino acids in 
the N-terminal that play fundamental roles in Gal-3 function, most importantly the 
position of an apoptosis- and metastasis-related phosphorylation site, Ser6. This new 
structure with the N-terminal section sets the path for the elucidation of full-length 
Gal-3 structure and its pharmacological applications. 
 
To date, a total of 15 members have been identified in the galectin family plus a few 
related proteins that closely share their sequence. A comprehensive genetic mapping 
of this family identified one particular Galectin-Related Protein (formerly known as 
HSPC159, now GRP) located in bone marrow that has a high degree of identity with 
galectins sequence, sharing their jelly-roll characteristic motif. This GRP is present 
only in vertebrates, unlike its ubiquitous relatives. Interestingly, GRP does not bind 
-galactosides. Human GRP structure has been reported twice with no further infor-
mation in its function. In order to study in detail the entirety of the galectin family 
for identifying themes of divergence and recognition within a limited number of pro-
teins, Gallus gallus GRP was chosen as model. Crystals of this protein belonged to 
the body-centered orthorhombic space group I212121 and had a resolution of 1.5 Å. 
Their crystallographic resolution showed the particular hallmarks that hinder -ga-
lactoside binding, indicating the development of a distinct function at the canonical 
lectin activity’s expense. 
xi 
 
RESUMEN 
 
La familia de las galectinas comprende proteínas de unión a -galactósidos presentes 
en una amplia variedad de organismos, de mamíferos a hongos y procariotes, donde 
cumplen funciones que pueden ser activadas por interacciones con carbohidratos o 
con otras proteínas. Las galectinas fueron clasificadas, con base en sus características 
estructurales, en prototípicas, tándem y quiméricas. Las prototípicas pueden formar 
homodímeros y las tándem forman heterodímeros del dominio de reconocimiento de 
carbohidratos (CRD), en tanto que las galectinas quiméricas tienen un domino N-
terminal distintivo, que comprende un péptido líder y nueve repeticiones Pro/Gly (N-
PG), unido al CRD en el C-terminal. En humanos, la única galectina quimérica es 
Galectina-3 (Gal-3). La resolución estructural del módulo N-PG no había sido con-
seguida, a pesar de la existencia de numerosos reportes del CRD de Gal-3. Haciendo 
uso de la ingeniería proteica, se produjeron construcciones de Gal-3 con distintas 
longitudes del N-PG para ensayos de cristalización. Una construcción que contiene 
el péptido líder y las repeticiones VII-IX del N-PG (Gal-3[N VII-IX]) cristalizó con 
alta reproducibilidad. Los cristales pertenecen al grupo espacial ortorrómbico 
P212121 y tienen una resolución de 2.2 Å. Estudios posteriores fueron realizados por 
dispersión de ángulo pequeño (SAXS). Los resultados de los experimentos para la 
caracterización estructural de Gal-3[N VII-IX] permiten localizar la posición de ami-
noácidos que juegan un papel fundamental en la función de Gal-3, en especial la 
posición de un sitio de fosforilación que media procesos de apoptosis y metástasis, 
Ser6. Esta nueva estructura con el [N VII-IX] es el primer paso en la elucidación de 
la estructura completa de Gal-3 y de sus aplicaciones farmacológicas. 
 
En total, 15 miembros han sido identificados en la familia de las galectinas, junto 
con otras proteínas relacionadas. Un estudio genético completo identificó en parti-
cular una proteína de la médula ósea asociada a galectinas (GRP, antes conocida 
como HSPC159), con un alto grado de identidad en su secuencia y que comparte el 
mismo plegamiento jelly-roll. GRP está presente únicamente en vertebrados, a dife-
rencia de las galectinas. Cabe resaltar que GRP no une -galactósidos. La estructura 
de GRP humana ha sido reportada dos veces sin profundizar en sus funciones. Para 
estudiar en detalle a la familia entera de galectinas e identificar puntos de divergencia 
y reconocimiento en un número limitado de proteínas, se escogió como modelo a la 
GRP de G. gallus. Los cristales de esta proteína pertenecen al grupo ortorrómbico 
I212121 y tienen una resolución de 1.5 Å. La estructura de GRP mostró las caracte-
rísticas específicas que impiden la unión de -galactósidos, resaltando el desarrollo 
de una función distintiva a expensas de la actividad canónica de galectinas.  
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INTRODUCTION 
 
Defined in a broad sense, glycobiology is the study of carbohydrates, including the 
chemistry and structure of saccharides, the enzymology of glycan formation and deg-
radation, the recognition of glycans by specialized proteins, the formation of gly-
coconjugates, the roles of glycans in complex biological systems and their analysis 
and manipulation. Taken together with the fact that they encompass some of the ma-
jor post-translational modifications of proteins themselves, glycoconjugate-forming 
carbohydrates help to explain how the relatively small number of genes in the typical 
genome can generate the enormous biological complexities inherent in the develop-
ment, growth and functioning of intact organisms. Microscopic studies of cells re-
vealed that these glycoconjugates, with extensive glycosylation, both in frequency 
and chain length, coat the cell surface in a complex network termed glycocalyx 
(Varki et al 2009; Lichtenstein and Rabinovich 2013). Certain changes in the cell 
expression of glycans and glycoconjugates are often found in the course of transfor-
mation and progression to malignancy, metastasis-associated processes including an-
giogenesis and immune escape, as well as other pathological situations such as in-
flammation and autoimmunity, the precise mechanisms of which are understood in 
only a few cases (Rabinovich and Thijssen 2014; Cagnoni et al 2016).  
 
With the growing awareness that the significance of glycosyl residues is to impart a 
discrete recognition role to receptors, glycans have now been recognized to have 
information-coding ability previously assigned exclusively to proteins. Indeed, in 
terms of coding capacity, the theoretical number of all possible oligosaccharides iso-
mers built from monosaccharides is several orders of magnitude larger (1.44 x 1015) 
than peptides (6.4 x 106) and oligonucleotides (4096). Therefore, for medical and 
biotechnological reasons, the study of both carbohydrates and their recognition pro-
teins is becoming increasingly relevant (Gabius et al 2011). 
 
1. CELL GLYCOSYLATION 
Glycosylation of the cell occurs by ensemble of monosaccharide building blocks 
with each other and with other molecules. Monosaccharides are imported into the 
cell, salvaged from degraded glycans, or derived from other sugars within the cell. 
Although most glycosylation reactions occur in the Golgi apparatus, precursor acti-
vation and interconversion occur mostly in the cytoplasm. Regardless of their local-
ization, most glycosylation reactions use activated forms of monosaccharides as do-
nor for reactions that are catalyzed by enzymes such as glycosyltransferases and gly-
cosidades. These enzymes link monosaccharides moieties into linear and branched 
BACK TO OUTLINE 
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glycan chains. They catalyze a group-transfer reaction, with either inversion or re-
tention of stereochemistry at the anomeric carbon atom of the donor substrate, in 
which the monosaccharide moiety of a single activated sugar donor substrate is trans-
ferred to the acceptor substrate. Generally, strict donor, acceptor, and linkage speci-
ficity are exhibited by most glycosyltransferases, a property that serves to define and 
limit the number and type of glycan structures observed in a given organism. Sub-
strates include other saccharides, lipids, small organic molecules, DNA, and pro-
teins. The main carbohydrate constituents of cellular glycans differ only in the rela-
tive positioning of one or two hydroxyl groups, thus epimerization must have sub-
stantial consequences for protein recognition of the sugars. The two general classes 
of protein-bound glycans in glycoconjugates are N-linked (to the N atom of Asn side 
chain), and O-linked (to the O atom of Ser/Thr side chains) (Varki et al 2009).  
 
Certainly, nature appears to have taken full advantage of the vast diversity of glycans 
expressed in organisms by evolving protein modules to recognize discrete glycans 
that mediate specific physiological or pathological processes. Conjugation of sugars 
to proteins occurs throughout the entire phylogenetic spectrum, with a known total 
of 13 monosaccharides and 8 amino acids forming at least 41 types of glycosidic 
linkages (Fig 1). Interestingly, a group of 250-500 genes is devoted to the synthesis 
and remodeling of glycan chains. Many glycans and glycoconjugates more specific 
biological roles are recognized via Glycan-Binding Proteins (GBPs): in fact, there 
Fig 1. The two general classes of protein-bound glycans in glycoconjugates are N-linked and O-
linked. Multiple LacNAcs may be presented on the branches of N-glycans or occur as polyLacNAc 
chains on either N- or O-linked glycans. Generation of polyLacNAc sequences is regulated in part by 
the family of core 2 -1,6-N-acetylglucosaminyltransferase branching enzymes for O-glycans and -
1,6-N-acetylglucosaminyltransferase V branching enzyme for N-glycans (Hernández and Baum 2002; 
Rabinovich and Toscano 2009). 
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3 
 
are no living organisms in which GBPs have not been found (Varki et al 2009; Ga-
bius et al 2011; Voet et al 2013).  
 
2. GLYCAN-BINDING PROTEINS 
Glycan-binding proteins are often glycoproteins themselves, synthesized in the 
ER/Golgi pathway (EGP). However, a significant subset of soluble GBPs, such as 
galectins, heparin-binding growth factors and some cytokines, are synthesized on 
free ribosomes in the cytoplasm and then delivered directly to the exterior of the cell. 
This makes functional sense, since several of these lectins can recognize biosynthetic 
intermediates that occur in the EGP, e.g., galactosides and high-mannose oligosac-
charides. Once secreted, glycan-binding sites of GBPs tend to be of a relatively low 
affinity though they can exhibit high specificity. The ability of such low affinity sites 
to mediate biologically relevant interactions in the intact system thus usually requires 
multivalency (Rabinovich et al 2002a). 
 
2.1. Types of lectins 
Lectins, from the Latin “leggere” (to select), were traditionally defined as “hemag-
glutinating, multivalent carbohydrate-binding proteins that are not antibodies”. Since 
many lectins may function as signaling molecules, their multivalency may promote 
cross-linking of relevant cell-surface receptors and may be required for signaling.  
 
A central question in lectin biology is how the exquisite target specificity of these 
proteins for certain cellular glycans can be explained. For instance, some lectins have 
a circumscribed set of immune function, which tether circulating leukocytes to in-
flamed endothelium to initiate the process of diapedesis. Transmembrane calcium-
dependent lectins recognize various types of danger signals from both microbial 
pathogens and damaged or altered host cells. Soluble lectins like ficolins, collectins, 
and mannose-binding protein opsonize microbial pathogens. Siglecs regulate leuko-
cyte activation. The first evidence on animal lectins (agglutinin activity) presented 
in the studies of Ginsburg in the 1960s, in which blood leukocytes from rats were 
treated with bacterial glycosidases and then injected back into the circulation (Varki 
et al 2009; Gabius et al 2011; Thiemann and Baum 2016).  
 
At the present time, there is no single universally accepted classification of lectins, 
though it is based in sequence homologies and evolutionary relationships. Accord-
ingly, the following classification is widely accepted: 
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2.1.1. R-type lectins. – Members of this subfamily contain a structurally similar CRD 
to the one in ricin, the first lectin discovered. R-type lectins are present in bacteria, 
plants and animals (Varki et al 2009; Bassik et al 2013).  
 
 
 
2.1.2. L-type lectins. – This subfamily was first discovered in the seed of legu-
minous plants. It is now known that they have structural motifs present in other 
eukaryotic organisms’ GBPs (Varki et al 2009; Cooper 2002).  
 
R-type 
PDBID: 1RTC 
L-type 
PDBID: 3NWK 
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2.1.3. P-type lectins. – These proteins specifically recognize mannose-6-phos-
phate. After binding to this sugar, they regulate lysosomes trafficking in the cells 
(Varki et al 2009).  
 
 
2.1.4. C-type lectins. – These lectins are Ca2+-dependent glycan-binding proteins 
that share primary and secondary structural homology in their CRDs, and are 
found in all organisms. This large family includes collectins, selectins, endocytic 
receptors and proteoglycans. Some of these proteins are secreted and others are 
transmembranal. Their capability for oligomerization increases their avidity for 
multivalent ligands. The first reported lectin in animal cells was of this type, the 
hepatic glycoasialoprotein receptor (Varki et al 2009). 
 
P-type 
PDBID: 2RL7 
C-type 
PDBID: 1PW9 
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2.1.5. I-type lectins. – These are proteins that belong to the immunoglobulin su-
perfamily (>500 protein-predicted genomes), excluding antibodies and T-cell re-
ceptors. The Siglec family of sialic acid-binding lectins is the only well-charac-
terized group of I-type lectins, both structurally and functionally (Varki et al 
2009; Cagnoni et al 2016).  
 
 
2.1.6. Galectins. – Galectins are described as -galactoside-containing glycocon-
jugates that share a highly conserved primary structural homology in their CRDs. 
Composed by 15 members in mammals, this family adds by sequence similarity 
other galectin-like proteins (Cooper 2002; Leffler et al 2004; Varki et al 2009).  
 
I-type 
PDBID: 1QFO 
Galectins 
PDBID: 1A3K 
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3. THE GALECTIN FAMILY  
The galectin family is evolutionarily ancient with representatives in vertebrates, in-
vertebrates, fungi and even protists. The presence of galectins in so many species, 
including very ancient ones, implies that they evolved to play fundamental roles in 
cell biology, while the presence of multiple galectins within single species suggests 
that they have since diverged to participate in a variety of more specific functions 
(Cooper 2002).  
 
During studies on the possible presence of galectins in the electric organs of the elec-
tric eel in 1975, a protein that required the inclusion of -mercaptoethanol in isola-
tion buffers to maintain its activity was found, suggesting the presence of one or 
more free Cys residues, thus galectins were originally referred to as S-type lectins. 
Later on was discovered that the transitions from free sulfhydryl groups to disulfide 
bridges appear to trigger shape changes. These redox-dependent shape changes, hav-
ing potential as switches to intersubunit or intrasubunit disulfide bridges upon oxi-
dation, suggest that the presence of Cys residues has a functional dimension. How-
ever, electrolectin, unlike most galectins, does not contain Cys residues but its key 
Trp residue in the carbohydrate-binding site can be oxidized, causing loss of activity 
(Teichberg et al 1975; Varki et al 2009). 
 
In the early 1980s, a 35 kDa GBP (CBP35, now known as galectin-3), with capacity 
for -galactoside binding was identified from mouse fibroblasts. All of the galectins 
discovered until then demonstrated hemagglutinin activity, but the choice of eryth-
rocytes was crucial. Tripsinized rabbit erythrocytes, which display more terminal 
galactose residues than human erythrocytes, are readily agglutinated by most galec-
tins, whereas human’s require treatment with neuraminidase to enhance their agglu-
tinability. The nomenclature for galectins was systematized in 1994. The first galec-
tin found (electrolectin) was renamed galectin-1 (Gal-1), its nearest homolog was 
termed Gal-2, and CBP35 (also named ɛBP, L-29, and L-31) was termed Gal-3. The 
subsequent galectins discovered were numbered consecutively by order of discovery 
(Cowles et al 1990; Cooper 2002; Varki et al 2009). 
 
Proceeding from the identification of the jelly-roll topology, with capacity to accom-
modate glycans and a common sequence signature, the systematic search for homol-
ogous proteins in a species and in phylogenesis stood as the next step on the way 
toward network analysis of galectins. The results of respective data base mining then 
set the stage to characterize expression and the localization profile as well as func-
tional cooperation of all members of the corresponding family of lectins, which have 
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arisen from an ancestral gene by divergence through duplications/losses and se-
quence deviations. Indeed, using BLAST and PSI-BLAST search algorithms to 
screen genomic and mRNA databases for sequences similar to known galectins, Alt-
schul et al (1997) identified many potential vertebrate and invertebrate candidates 
for membership in the galectin family, as well as new human galectin-related pro-
teins. Certain other galectin-like genes appeared to be pseudogenes, for instance be-
cause stop codons interrupt their CRDs. A total of 15 galectins have now been found 
in mammals, but only 12 galectin genes are found in humans, including two for ga-
lectin-9 (Altschul et al 1997; Gabius 2000; Cooper 2002; Thijssen et al 2013).  
 
Although much is known about galectins, mechanisms of action remain unknown. 
Galectins can function intracellularly and can also be secreted to bind to cell surface 
glycoconjugate counterreceptors, though the secretion pathway of galectins is highly 
unidentified as of today. Some galectins are made by immune cells, whereas others 
are secreted by cells such as endothelial or epithelial cells. Galectin-binding to a 
single glycan ligand is a low-affinity interaction, but the multivalency of galectins 
and the glycan ligands presented on cell surface glycoproteins result in high-avidity 
binding that can reversibly scaffold or cluster these glycoproteins. The binding of 
galectins to other glycoproteins is mostly regulated by several enzymes that mediate 
carbohydrate ligands expression by a cell. Furtherly, the effect of binding avidity in 
galectins is a result of ligand clustering or retention by these glycoprotein counterre-
ceptors (Gabius et al 2011; Rabinovich and Thijssen 2014; Thiemann and Baum 
2016). 
 
Lastly, the detection of a Galectin-Related Protein (GRP) has its origin in gene ex-
pression cataloguing of human CD34+ hematopoietic stem/progenitor cells that led, 
among 300 cDNA clones, to an mRNA termed HSPC159 (Cooper 2002). Systematic 
alignments of its predicted amino acid sequence disclosed that it encompasses 51 
positions of the 64 amino acids set most shared among galectins. Presence of the 
gene has been found to be exclusive of vertebrates, and initial comparison revealed 
an exceptionally high degree of similarity that implies a very strong positive selec-
tion. As predicted by sequence homology, GRP preserves the jelly-roll topology but 
it does not bind galectins’ canonical ligands. Sequence conservation at a high level, 
as seen for GRP genes in vertebrates, is a sign for the development of a distinct 
function at the canonical lectin activity’s expense (Wälti et al 2008a; Ruiz et al 
2014).  
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3.1. Galectins classification and function 
It is remarkable that -galactosides at the branch ends of glycan antennae of cell 
surface glycoconjugates are not only accessible for molecular recognition as sensors, 
but they are also subject of an array of enzymatic substitutions, such as 2,3-sialyla-
tion. These structural alterations are very specific, as they modulate the ligand prop-
erties of the respective glycans to galectins. Through these interactions, galectins 
mediate multiple cellular responses, which harbor their ideal properties as high-den-
sity storage of biological information (Gabius 2009; Vasta et al 2012). 
 
Most galectins are non-glycosylated soluble proteins, but a few exceptions have 
transmembrane domains. Although galectins lack a typical secretion signal peptide, 
they are present not only in the cytosol and the nucleus (where they are engaged in 
processes such as pre-mRNA splicing and protein regulation), but also in the extra-
cellular space. From the cytosol, galectins may be targeted for secretion by non-clas-
sical mechanisms, possibly by direct translocation across the plasma membrane. In 
the extracellular space, galectins can bind to glycans at the cell surface and/or the 
ECM, and to potential pathogens. Galectin-mediated lipid raft assembly may mod-
ulate turnover of endocytic receptors and signal transduction pathways (Yang et al 
2008; Vasta et al 2012).  
 
The expression of galectins is modulated during the differentiation of individual cells 
and during the development of organisms and tissues, and is changed under different 
physiological or pathological conditions. Importantly, in most cases, protein-protein 
interactions, rather than lectin-carbohydrate interactions, are involved (Liu et al 
2002). 
 
Based on their domain organization, galectins are classified in three types (Fig 2):  
 
(i) Proto-type galectins contain one CRD per subunit and are non-covalently 
linked homodimers.  
 
(ii) Tandem-repeat galectins have two CRDs joined by a functional linker pep-
tide ranging from 5 to 50+ amino acids in length. 
 
(iii) Chimera galectins have a C-terminal CRD, and a distinct N-terminal do-
main rich in proline and glycine (N-PG) that contributes to self-aggrega-
tion. 
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Prototypic 
Tandem-re-
peat 
Chimera 
Fig 2. Galectin types and lattices. Proto-type galectins (blue) are most commonly non-covalently linked 
homodimers, tandem-repeat type (red) are usually heterodimers joined by a functional linker, and chimera-
type (purple) have a C-terminal CRD and a distinct N-terminal for multimerization. Galectins bind to cell 
surface -galactoside-containing glycolipids and glycoproteins leading to the formation of lattices that clus-
ter these ligands into lipid raft microdomains required for optimal transmission of signals relevant to cell 
function. Distinct types of lattice that can be formed hypothetically between multivalent galectins and mul-
tivalent glycans, such as trivalent (prototypical), tetravalent (tandem-repeat) and bivalent (Gal-3), are illus-
trated (Rabinovich and Toscano 2009). 
 
Trivalent ligand lattice 
Tetravalent ligand lattice 
Bivalent ligand lattice 
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Proto and tandem-repeat types comprise several separate galectin subtypes. Galec-
tin(Gal)-1, -2, -5, -7, -10, -11, -13, -14 and -15 are prototypical, Gal-4, -6, -8, -9 and 
-12 are tandem-repeat, and Gal-3 is the only chimera type in vertebrates (Gabius et 
al 2004; Solís et al 2010). The association of proto-type galectin monomers as non-
covalently bound dimers via a hydrophobic interphase is critical for their function in 
mediating interactions, lattice formation localized at the cell surface, and down-
stream effector functions. Tandem-repeat galectins can recognize different saccha-
ride ligands with a single polypeptide, although they can also form higher order ag-
gregates that enhance their avidity. For the chimera galectins, oligomerization takes 
place via the N-PG domain to form trimers or pentamers that, in the presence of 
multivalent oligosaccharides in solution or at the cell surface, display binding coop-
erativity (Fig 2) (Rabinovich et al 2002a; Vasta et al 2012). 
 
Susceptibility to galectins is controlled by the cell and may be regulated at three 
levels: (1) synthesis and modification of glycan ligands by glycosyltransferases and 
glycosidases, (2) presentation of glycan ligands by specific glycoprotein counterre-
ceptors, and (3) intracellular signaling pathways initiated by galectin binding to gly-
coprotein counterreceptors.  
 
However, the translational and clinical applications of altered glycan structures have 
not yet been completely accomplished, probably due to the complex regulation of 
the glycosylation: heterogeneity is inherent to the language of glycans and crucial 
for their diverse biological roles as information carrier for lectins (Hernández and 
Baum 2002; Cagnoni et al 2016).  
 
While Gal-1 and -3 are detected ubiquitously, other galectins are more specifically 
located, such as Gal-2 and -4, which are preferentially found in the gastrointestinal 
tract, Gal-7 is highly abundant in skin tissue, Gal-10 in eosinophils, and Gal-12 in 
adipose tissue (Cagnoni et al 2016). That is, individual galectins can act on multiple 
cell types and multiple galectins can act on the same cell (Fig 3). 
  
Cancer regulation: Different galectins have discrete yet complementary roles in the 
regulation of tumor progression. There is direct evidence that Gal-1 and -3 expres-
sion is necessary for the initiation of the transformed phenotype of tumors. Onco-
genic Ras requires Gal-1 mediated anchorage to the plasma membrane, and Gal-1 
expression also results in the sustained activation of RAF1 and ERK. Gal-3 pro-
motes the activation of RAF1 and PI3K, and contributes to the selective activation 
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of signaling cascades and the regulation of gene expression at the transcriptional 
level (Liu and Rabinovich 2005; Gao et al 2014).  
 
Apoptosis regulation: To date, only two families of proteins have been described as 
death-inducing ligands: the TNF family of proteins and the galectin family. Pro-
apoptotic galectins bind to specific saccharide ligands on cell surface glycoproteins 
and/or glycolipids to initiate cell death (Hernández and Baum 2002). In Gal-3, the 
NWGR sequence motif, found in Bcl-2 and other apoptosis-regulating proteins, has 
been implicated in the intracellular anti-apoptotic effectS of Gal-3 in tumorous cells, 
therefore contributing to the survival of metastasizing tumor cells. On the other hand, 
Gal-1 inhibits full T cell activation, induces the growth arrest and apoptosis of acti-
vated T cells, and suppresses the secretion of pro-inflammatory cytokines (Umemoto 
et al 2003; Liu and Rabinovich 2005; Lichtenstein and Rabinovich, 2013).  
 
Metastasis: Gal-3 acts as a mediator in both vascular endothelial growth factor 
(VEGF) and hematogenous metastasis, basic fibroblast growth factor (bFGF)-medi-
ated angiogenic response and cell adhesion to the endothelium (Glinsky et al 2003; 
Markowska et al 2011). Interestingly, galectins recognize, in a carbohydrate-depend-
ent manner, one of the most extensively studied families of cell adhesion molecules: 
the integrins. Gal-3 upregulates integrin expression. The level of Gal-1 expression 
is positively correlated with the migratory phenotype and biological aggressiveness 
of human astrocyte tumors. Gal-8 ligates integrins and triggers integrin-mediated 
signaling cascades, resulting in cytoskeletal changes and cell spreading (Liu and 
Rabinovich 2005).  
 
Inflammation and infection: Some galectins are amplifiers of the inflammatory re-
sponse, whereas others activate homeostatic signals to shut off immune effector 
functions. Gal-1 recognizes a number of cell-surface glycoproteins in T cell lines in 
a carbohydrate-dependent manner, and can cause a redistribution of some of these 
proteins into segregated microdomains within the plasma membrane. Gal-3 induces 
the activation of various inflammatory cell types and can function like a chemokine, 
attracting monocytes and macrophages. Gal-3 might also reduce the immune re-
sponse under certain circumstances by downregulation of IL-5 production and 
blocking the differentiation of B lymphocytes into plasma cells, with the conse-
quences being reduction of antibodies. Gal-2 can induce T cell apoptosis and control 
the secretion of lymphotoxin- by macrophages. Gal-4 activates CD4+ T cells. Gal-
9 can also induce T cell apoptosis and function as an eosinophil chemoattractant. 
Besides mediating endogenous functions, and innate as well as adaptive immune 
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processes, galectins also bind exogenous glycans on the surface of potentially path-
ogenic microbes (Frigeri et al 1994; Liu et al 1995; Rabinovich et al 2002b; Niemi-
nen et al 2005; Vasta et al 2012).  
 
Other functions: Finally, their expression has been found in non-infectious, non-car-
cinogenic diseases such as arthritis, chronic inflammation, heart failure and diabetes. 
Galectins are highly expressed at the maternal-fetal interface, and their dysregulated 
expression is observed in the great obstetrical syndromes (Than et al 2012; Lichten-
stein and Rabinovich 2013; Thijssen et al 2013; Gao et al 2014). 
 
 
  
mRNA splicing 
glycosylated receptors 
apoptotic 
angiogenic 
cytoplasm 
nucleus 
citostatic mitochondrion 
metastasic 
Fig 3. Galectins’ biological functions. Both in self-association or association with other galectins, 
these proteins are able to selectively promote or inhibit cell death, as well as being mRNA splicing 
factors and cell-cycle regulators (Liu and Rabinovich 2005). 
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4. STRUCTURAL CHARACTERIZATION OF GALECTINS AND GRP  
The CRD of most galectins is composed of a five-stranded (F1–F5) and a six-
stranded (S1–S6) anti-parallel -sheets connected by a 310 helix, forming a -sand-
wich arrangement, a folding called jelly-roll. In the canonical dimeric galectins-1 
and -2, -strands F1 and S1 from each monomer extend the antiparallel beta-strand 
interactions across the two-fold symmetry at the dimer interface, whereas the S1 and 
F1 beta-strands of galectin-3 form a solvent-exposed surface. The carbohydrate bind-
ing site is formed by three continuous concave strands (4–6) containing all key resi-
dues for binding, such as His45, Asn47, Arg49, Arg70, Glu68 and Trp65 (number-
ing is for Gal-2), that are involved in direct interactions with -galactosides (Fig 4). 
Galectin-Related Protein and even some viral galectins share this topology (Seetha-
raman et al 1998; Wälti et al 2008a; Vasta et al 2012; Thiemann and Baum 2016).  
 
It is generally accepted that galectins require three OH groups of Gal1-
3/4(Glc/Gal)NAc units, the 4-OH and 6-OH groups of galactose, and the 3-OH 
group of (Glc/Gal)NAc. Some galectins also show a particular preference for 1-
2Fuc-, 1-3Gal-, 1-3GalNAc-, or 2-3NeuAc-modified glycans (Hirabayashi et 
Fig 4. “Jelly-roll” folding and Carbohydrate Recognition Domain of Galectins. Galectins’ CRD is 
tightly folded in a -sandwich folding called jelly roll, with the CRD site between strands S4-S6 
(Seetharaman et al 1998). 
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al 2002). For instance, the crystal structure of Gal-3 co-crystallized with Gal1-
3/4GlcNAc disaccharides revealed that the Asn180, Trp181 and Gly182 amino ac-
ids are important for recognition of galactose (Sorme et al 2005). The amino acids 
interacting with the docked oligosaccharide in the active sites of lectins are im-
portant, but so are the surface-exposed amino acids that orient glycans spatially and 
participate in their movement into the active site (Nahalka 2012). 
 
4.1. Galectin-3 
Galectin-3 (Gal-3), a 29-kDa protein, is the only chimera type galectin, with a CRD 
domain joined to an N-terminal domain with several repeats of a peptide sequence 
rich in proline and glycine (N-PG) that is similar to collagen repeating domains (Ga-
bius et al 2011; Vasta et al 2012). The C-terminal half, composed of approximately 
130 amino acids, that forms a globular structure, accommodates the entire carbohy-
drate-binding site and is thus responsible for the lectin activity of Gal-3. The N-PG 
contains 110-130 amino acids and is highly conserved among different species 
(Dumic et al 2006; Elola et al 2007). Different parts of the N-PG have been sub-
classified into a short N-terminal leader domain (N-LD), which corresponds to the 
first 12 amino acids, and the collagen-like repeats, which contain I–IX repeats of 
short amino acid segments Pro–Gly–Ala–Tyr–Pro–Gly (Gong et al 1999; Cooper 
2002; Nangia-Makker et al 2007). 
 
 
Self-association of Gal-3 has been reported to be mostly dependent on the N-PG 
domain (Rabinovich et al 2007; Rapoport et al 2008). Since Gal-3 displays di- or 
oligomeric conformations that enable ligand cross-linking or high-affinity binding 
of clustered ligands to multiple CRDs, the involvement of the N-PG tail in these 
properties have been studied in a number of chemical and physiological scenarios 
(Liu and Rabinovich 2005; Kaltner et al 2011; García, Flores-Ibarra, Michalak et al 
2016).  
 
It seems that the N-PG region accounts for Gal-3 oligomerization via tail-to-tail in-
teraction, for instance, in the experiments of Kaltner et al (2011), since the proteol-
ysis of the N-terminal repetitive domain by metalloproteinase-2 and -9 (MMP-2, -
Gal-3 N-LD I II III IV V VI VII VIII IX CRD 
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9) leaves an intact C-terminal galectin domain with full lectin activity but losing 
much of the Gal-3 propensity to multimerize (Kaltner et al 2011).  
 
A methodology based on the measurement of residual dipolar couplings from NMR 
spectra was used to characterize differences in protein structure along the backbone 
in the presence and absence of ligand, as well as the binding geometry of the ligand 
itself. The data on -galactoside ligands are consistent with the ligand binding ge-
ometry found in Gal-3 crystal structures of the complexed state. However, a signifi-
cant rearrangement of backbone loops near the binding site appears to occur in the 
absence of ligand (Umemoto et al 2003).  
 
Gal-3 may be transported to the early/recycling endosomes and then partitioned into 
two routes – recycling back to the plasma membrane or targeting to the late endo-
somes/lysosomes. The carbohydrate-recognition domain of galectin-3 was required 
for its binding and endocytosis. The N-PG alone could not mediate binding and en-
docytosis alone. Although it was largely irrelevant the protein trafficking to the 
early/recycling endosomes, the N-PG domain was required for targeting Gal-3 to the 
late endosomes/lysosomes. The short N-LD was irrelevant to both binding and in-
tracellular trafficking (Gao et al 2012). Moreover, the CRD alone fails to support 
neutrophile adhesion, and fails to induce migration and capillary tubule formation in 
endothelial cells in vitro and angiogenesis in vivo, further underscoring N-PG’s im-
portance (Sato et al 2002; Nangia-Makker et al 2007). 
 
The first evidence of this was given by the crystal structure of its CRD (Seetharaman 
et al 1998). Although associations involving both the N- and C-terminal domains 
could easily be achieved by a parallel orientation of monomers, an arrangement seen 
in the collectins (Drickamer 1993), analysis of the Gal-3 CRD revealed an apolar 
patch in the face of the 5-stranded beta-sheet which may provide a site for monomer-
monomer interactions. Thirty Gal-3 CRD structures have been solved by X-ray crys-
tallography ever since. However, with all this data about Gal-3’s CRD, to this day, 
nineteen years after the first crystal structure reported, there is no solved structure of 
the CRD with the N-PG domain (http://www.rcsb.org/pdb). NMR studies have 
shown that the N-terminal domain of Gal-3 is highly flexible in solution (Seetha-
raman et al 1998; Birdsall et al 2001), which may account for the difficulty to crys-
tallize it.  
 
This region plays an as yet structurally ambiguous role in Gal-3 aggregation and 
ligand recognition. Results of mutation studies revealed that the N-PG has biological 
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importance in binding: the intact Gal-3 has a 3.8-fold higher affinity for carbohy-
drates than the CRD itself (Funasaka et al 2014b). The affinity difference suggests 
that the N-terminal non-CRD contributes to the enhanced affinity of Gal-3 for the 
extended structures of the basic recognition units and the ability to recognize further 
carbohydrates and/or proteins. Of note, cis-binding to cell surface counterreceptors 
and trans-binding for cell bridging depend on distinct N-PG properties. However, 
for instance, Gal-3 with MMP truncation did not impair cell proliferation and 
hemaagglutination, unless left only the CRD alone, and sometimes the cleavage even 
induced angiogenesis in cancer models (Nangia-Makker et al 2010). The application 
of engineered Gal-3 N-PG variants of different lengths offers a promising perspec-
tive to delineate detailed structure-activity profiles (Ochieng et al 1994; Hirabayashi 
et al 2002; García, Flores-Ibarra, Michalak et al 2016). 
 
4.2. Galectin-Related Protein 
Shared exon-intron organization suggests that vertebrate galectins originated from 
an ancestral mono-CRD galectin by gene duplication, divergence and subfunction-
alization. Systematic alignments of the predicted sequence of a galectin-related pro-
tein (GRP) in human HSPCs disclosed its similarity to galectins. Comprehensive 
listing of the currently mapped species with positivity for the GRP gene showed that, 
in all cases, the copy number for the protein is one (Fig 5) (Cooper et al 2002).   
 
The region of the CRD following the N-terminal tail in GRP is highly conserved, as 
it is the second part of the 36-amino acid N-terminal section. A peculiar feature is 
seen at the central position in the CRD of canonical galectins: the Trp moiety, which 
establishes carbohydrate/ (CH/) contacts to a ligand’s galactose residue, is present 
in birds, fish and amphibians in the same place as galectins, whereas mammals con-
sistently present a substitution by Arg/Lys. Still, the most notable feature of GRP is 
its lack of -galactosides binding activity, in spite of its sequence correspondence 
with canonical galectins.  
 
Over 200 compounds, comprising glycans, [lipo]polysaccharides and glycosamino-
glycans have been tested by microarray to cover a wide spectrum of glycan structures 
that might bind to C-GRP, along with CG-1A, -1B and -2 as positive controls, but 
no significant reactivity between biotinylated C-GRP and any glycocompound could 
be detected. This has an analogy in C-type lectin-like domains that have lost capacity 
to bind sugars but have gained reactivity to other types of epitopes (Wälti et al 2008b; 
Ruiz et al 2015; García, Flores-Ibarra, Michalak et al 2016). Because GRP is a hem-
atopoietic precursor, it resides in specific niches that control survival, proliferation, 
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self-renewal, or differentiation of lymphocytes. In mammals, the continuous traffick-
ing of GRP between the bone marrow and blood compartments contributes to the 
maintenance of normal hematopoiesis. This trafficking is induced in adult animals 
by treatment with cytokines and/or cytotoxic drugs (Wright et al 2002; Katayama et 
al 2006), making the basis for innovative ligands to be come upon. 
 
The general pre-requisites for the adhesion/growth-regulatory galectin group are ful-
filled in the species Gallus gallus (common name, chicken) with a total of only five 
canonical proteins. There is also the occurrence of an expressed sequence tag with 
similarity to a bone marrow human galectin-related protein (GRP) found in chicken 
bursal lymphocytes (C-GRP), which indicates that a sixth member of this family is 
present in chicken. Moreover, C-GRP arises as an important protein, with very strong 
positive selection and because (i) this feature emerges from inter-species considera-
tions that imply special functionality, and (ii) the obvious requirement to bring char-
acterization of this chicken protein to the same levels as it has been done for the five 
canonical chicken galectins (CGs). Gallus gallus was chosen in this work in order 
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Fig 5. Galectin and GRP phylogeny. Members of the galectin family have arisen from an ancestral 
gene by divergence, though not all of them have canonical carbohydrate-binding activity. The de-
tection of a human Galectin-Related Protein revealed a protein with sequence similarity to galectins 
but unknown natural ligands, present in other orders notwithstanding not in other phyla (Cooper et 
al 2002; García, Flores-Ibarra, Michalak et al 2016). 
Homo sapiens 
Proto: eight 
Chimera: one 
Tandem: four 
GRP: one 
Gallus gallus 
Proto: three 
Chimera: one 
Tandem: one 
GRP: one 
Mus musculus 
Proto: three 
Chimera: one 
Tandem: five 
GRP: one 
Drosophila  
melanogaster 
Proto: one 
Tandem: four 
Danio rerio 
Proto: four 
Chimera: one 
Tandem: two 
GRP: one 
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to map the structures of all galectins to track down themes of recognition and diver-
gence, and to analyze the difference between mammals’ GRP structure (e.g. PDBID: 
2JJ6) and birds’ GRP structure (Oda and Kasai 1983; Cooper 2002; Wälti et al 
2008a; Ruiz et al 2015).  
 
In conclusion, the current insight into how sugar-encoded messages are translated by 
interactions between galectins and glycans provides a deep understanding into fun-
damental mechanisms, mediating cell activation, differentiation and death/survival, 
resolution of inflammation, chronic infection, autoimmunity and neurodegeneration 
(Lichtenstein and Rabinovich 2013; Solís et al 2015). Relevance of lectin-glycan 
recognition systems is, thus, undeniable. Drug design and specificity in effector mol-
ecules to activate, inhibit or change galectins’ functions are based on the structural 
studies of the protein of interest. Being its CRD solved nineteen years ago (Seetha-
raman et al 1998), no part of the N-PG domain has been solved thus far. Many of 
Gal-3 function relies in this domain, such as protein oligomerization, and post-trans-
lational phosphorylation in the N-LD Ser6 residue mediates a key change in the pro-
tein that activates its function in apoptosis, autophagy and nuclei transport into the 
cytoplasm (Lichtenstein and Rabinovich 2013). Structural knowledge in the N-PG 
section will complement the biological insights on Gal-3, for example, by pinpoint-
ing the accommodation of Ser6 in a Gal-3 oligomer or the properties for such oli-
gomerization. The high flexibility inherent to the N-PG has made it such a difficult 
task to crystallize it. By choosing a protein engineering approach (Kopitz et al 2014), 
this work produces the first structural resolution on a section of Gal-3 N-PG domain. 
On the other hand, a fully comprehensive study of the galectin family means resolv-
ing for all the types predicted by DNA database mining present in an organism. Be-
sides galectins, a particular Galectin-Related Protein has been described in all verte-
brates (but not in invertebrates), with a sequence homology that places it among the 
members of the galectin family but that lacks the main trait describing galectins: the 
ability to bind -galactosides. This binding is profusely described as to happen 
through specific H-bonds and CH/ interactions. A notorious difference between 
mammal GRP and avian GRP is that the former lacks the presence of the Trp residue 
responsible for the CH/ interactions with the galactose moiety, but it is present in 
the latter (García, Flores-Ibarra, Michalak et al 2016). Still, avian GRP does not bind 
-galactosides. This work answers to the necessity to study the difference with hu-
man GRP structure and the structural difference with canonic galectins that may ac-
count for its lack of binding to canonical ligands. The model of Gallus gallus is ideal 
for characterizing all galectin types present in vertebrates in a minimum amount of 
proteins.
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OBJECTIVES 
 
- To obtain high-purity samples of Gal-3[N VII-IX] for structural experiments. 
- To crystallize Gal-3[N VII-IX] and obtain good quality, good sized diffract-
ing crystals. 
- To determine the three-dimensional structure of Gal-3[N VII-IX] by X-ray 
crystallography. 
- To characterize Gal-3[N VII-IX] and Gal-3FL by biophysical techniques, in-
cluding Small-Angle X-ray Scattering. 
- To explain the participation of the N-terminal poly-Proline/Glycine domain 
in the Galectin-3 structure, that may shed light on function. 
 
- To obtain high-purity samples of C-GRP-C for structural experiments. 
- To crystallize C-GRP-C and obtain good quality and good sized diffracting 
crystals. 
- To determine the 3D-structure of C-GRP-C and compare the structure to that 
of human GRP-C. 
- To characterize biophysically the protein by means of Small-Angle X-ray 
Scattering and Analytical Ultracentrifugation. 
- To relate the lack of affinity for -galactosides of the Galectin-Related Pro-
tein regarding its structure and cell location. 
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MATERIAL AND METHODS 
 
1. PROTEIN EXPRESSION AND PURIFICATION 
The group of Prof. Hans-Joachim Gabius at Ludwig-Maximilians University (Mu-
nich, Germany) provided purified samples of proteins human Galectin-3 and chicken 
Galectin-Related Protein. More specifically, studies were made with full length Gal-
3 (hGal-3FL) and a matrix metalloproteinase-processed form HUMAN GALECTIN-3 
DELETION MUTANT 23-75 (GAL-3[N VII-IX]), full length chicken Galectin-Re-
lated Protein (C-GRPFL) and CHICKEN GALECTIN-RELATED PROTEIN DELETION 
MUTANT 1-36 (C-GRP-C). As proof of concept and for further tests, cellular ex-
pression and purification of C-GRP-C was also made in-house. 
 
1.1. E. coli expression of C-GRP-C 
1.1.1. DNA cloning 
GRP synthetic cDNA was provided by ATG: biosynthetics GmbH (Merzhausen, 
Germany) and oligonucleotides GRPNdeI and GRPXhoI by Sigma-Aldrich (Mis-
souri, USA). Both the cDNA and oligonucleotides were stored at 253 K. 
 
First, cDNA was amplified using polymerase chain reaction (PCR) with the de-
signed specific primers, and a positive control, using KOD polymerase (Novagen, 
Merck Biosciences, New Jersey, USA) and dNTPs (Thermoscientific, Massachu-
setts, USA). The PCR protocol was: 
 
 
 
The melting temperature (Tm) was calculated using the following formula [since the 
Mastercycler (Eppendorf, Hamburg, Germany) used for these PCRs uses Celsius as 
temperature unit, calculations were made in Celsius degrees]:  
 
Tm = [(G + C) x 4 ºC] + [(A + T) x 2 ºC]   
Tm  Number of guanines and cytosines times four plus number of adenines and 
thymines times two. 
 
POOL MIXTURE 
Buffer for KOD Hot Start pol 10X 5 l 
dNTPs (2 mM) 5 l 
MgSO4 3 l 
H2O 32.5 l 
KOD polymerase 1 l 
DNA MIXTURE 
GRP cDNA 0.5 l 
NdeI 1.5 l 
XhoI 1.5 l 
Positive control 2 l 
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Tm = 64.3 ºC  
Reactions were prepared in 50 ml volumes with the followoing reaction conditions: 
 
 
 
 
 
 
 
 
PCR products were checked in a 1% agarose gel. Both GRP cDNA bands in the gel 
were cut out of the agarose gel and purified using a QIAquick PCR Purification Kit 
(QIAGEN, Hilden, Germany). 
 
1.1.2. DNA ligation 
Vectors for bacterial expression used for ligation of the GRP DNA fragment were of 
the pET28 series of vectors with a Poly-Histidine tag (pET28-PP) for conveying 
specificity to the protein for posterior purification. DNA insertion vector was di-
gested with NdeI and XhoI restriction enzymes using manufacturer’s protocol (New 
England Biolabs, USA): 
 
 
 
 
 
 
 
 
 
 
The digestion mix was left 3 hours at 310 K. Afterwards, the ligation of the GRP 
fragment was made, using the following protocol (New England Biolabs, USA). The 
ligation was done at room temperature with varying time from 2 hours to overnight. 
As negative control was used a ligation reaction without DNA insert: 
 
 
 
 
 
 
 
 
MASTERCYCLER PROGRAM 
Initial cycle 5 mins 98 ºC  
Denaturalization cycles 30 secs 98 ºC 
30 cycles Extension cycles 60 secs 60 ºC 
KOD Polymerase cycles 2 mins 72 ºC 
Final cycle 10 mins 70 ºC  
DIGESTION MIXTURE 
DNA vector 25 l 
Buffer 4 10X 6 l 
BSA 100X 0.6 l 
H2O 23.4 l 
NdeI 2.5 l 
XhoI 2.5 l 
LIGATION MIXTURE 
Buffer 10X T4 DNA ligase 1.5 l 
Vector 5 l 
GRP DNA fragment 5 l 
T4 DNA ligase 1 l 
H2O 2.5 l 
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1.1.3. DNA transformation 
The ligation reactions were transformed into Escherichia coli DH5 chemically 
competent  cells (Promega, Mannheim, Germany) by heat shock. 
 
Transformation of E. coli DH5 by heat shock [all in a sterile environment]: 
1. Mix 60 l of competent cells with 10 l of the ligation reaction and incubate for 
15 mins. 
2. Place cells for heat shock at 315 K for 1 min and 30 secs. 
3. Incubate cells at 277 K for 5 mins. 
4. Add 1 ml of 2XTY medium and place cells for recovery at 310 K for 1 hour on a 
shaker. 
5. Spin cells for 3 mins at 6708 g in a MiniSpin Plus centrifuge (Eppendorf, Ham-
burg, Germany) and decant or pipet out all but 50 l of volume. 
6. Resuspend cells in 200 l 2XTY medium and plate by massive streaking in LB 
agar containing kanamycin (KAN, 50 µg/mL). 
 
Plated cells were incubated overnight at 310 K to allow colonies to grow. Fifteen 
colonies were randomly selected and single-streaked into freshly LB-KAN agar 
plates. The remaining bacteria were placed in 20 l of MilliQ water (Millipore Co., 
Massachusetts, USA) and heated to 373 K for 2 mins to screen the colonies by PCR 
analysis. The colony PCR was performed following the protocol listed below with 
Taq polymerase (Invitrogen, California, USA) instead of high fidelity KOD poly-
merase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
POOL MIXTURE 
Buffer for TAQ pol 10X  
(with MgSO4) 
5 l 
dNTPs (2 mM) 5 l 
H2O 15 l 
TAQ polymerase 1 l 
DNA MIXTURE 
GRP-pET28 1 l 
Nde oligo (FW) 1.5 l 
Xho oligo (BW) 1.5 l 
Positive control 2 l 
MASTERCYCLER PROGRAM 
Initial cycle 5 mins 98 ºC  
Denaturalization cycles 30 secs 98 ºC 
30 cycles Extension cycles 60 secs 50 ºC 
KOD Polymerase cycles 90 secs 72 ºC 
Final cycle 10 mins 72 ºC  
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Positive colonies were identified in a 1% agarose gel and sequenced in the in-house 
service Secugen to confirm gene integrity. 
 
1.1.4. Heterologous protein over-expression 
Protein expression can be done in an E. coli host strain from a vector with a tag 
and/or fusion partner. The choice of the host strains depends more on the nature of 
the heterologous protein (Miroux and Walker, 1996). 
 
Once sequences were confirmed by DNA sequencing, plasmid DNAs were trans-
formed in BL21(DE3) electrocompetent cells with a MicroPulser electroporator (Bi-
oRad, California, USA), mixing 1 l of plasmid DNA in 90 l of cells and transfer-
ring the sample to a 0.1 cm electroporation cuvettes.  
 
For recovery after electroporation, cells were added 1 ml of 2XTY medium and in-
cubated 1 hour at 310 K on a shaker, before plating into LB-KAN plates. 
 
Single colonies were inoculated in 10 ml of 2XTY medium containing 50 g/ml 
kanamycin and incubated overnight on a 310 K shaker at 250 rpm. The overnight 
cultures were transferred into a flask with 950 ml of fresh 2XTY-KAN medium and 
left to grow at 310 K on a shaker until the optical density at 600 nm (OD600) reached 
~0.6-0.8. Protein expression was induced with IPTG (isopropyl -D-1-thiogalacto-
pyranoside, Gold Biotechnology, Missouri, USA) to a final concentration of 1 mM 
and incubated overnight on a 293 K shaker at 250 rpm (Rosano and Ceccarelli 2014; 
EMBL Protocols). 
 
Cell cultures were harvested by centrifugation for 15 mins at 6238 g in a JLA8.1000 
rotor (Beckman Coulter, California, USA) keeping it at 277 K during the entire pro-
cess. Cell pellets were resuspended in 40 ml of lysis buffer (50 mM Tris-HCl pH 7.5, 
500 mM NaCl, 0.5% Tween 20), and sonicated in a Misonix S4000 Sonicator 
(Hielscher Ultrasonics, Teltow, Germany). The lysate was put to centrifuge for 30 
mins at 200K g in a 45Ti rotor (Beckman Coulter, California, USA), at 277 K, and 
the supernatant was collected after centrifugation. 
 
1.2. Protein purification 
Purifying a protein to homogeneity is crucial for protein crystallization, as contami-
nants can hamper crystal growth. Protein purification via affinity chromatography is 
a powerful technique that separates biomolecules on the basis of a reversible inter-
action between a biomolecule and a specific ligand coupled to a stationary matrix. 
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Complementarily, size exclusion chromatography separates molecules based on their 
size in which molecules with partial access to the pores of the matrix elute from the 
column in order of decreasing size (www.gelifesciences.com/handbooks). As such, size 
exclusion was the final polishing step of purification.   
 
Gal-3[N VII-IX] 
Suspensions of precipitated material were dialyzed against PBS containing 4 mM -
mercaptoethanol (BME) with a Slide-A-Lyzer Dialysis Cassette (3500 MWCO, 
Thermo Scientific, Rockford, USA) followed by affinity chromatography on lacto-
sylated Sepharose 4B, to remove any inactive material. Eluted fractions were then 
checked by SDS-polyacrilamide gel electrophoresis (SDS-PAGE). Solutions were 
concentrated and loaded in a HiPrep 16/60 Sephacryl S-100 high-resolution column 
(GE Healthcare, Little Chalfont, UK) equilibrated with 20 mM Na+/K+–PO4 buffer 
pH 7.0 with 150 mM NaCl, 4 mM  and 5 mM lactose using an ÄKTA Prime 
system (GE Healthcare, Little Chalfont, UK), at flow rate 0.5 ml·min-1 and 277 K.  
 
The column was calibrated beforehand with the following molecular weight mark-
ers: blue dextran (Mr = 2000 kDa), aldolase (Mr = 158 kDa), albumin (Mr = 67 kDa), 
ovalbumin (Mr = 44 kDa), chymotrypsinogen (Mr = 25 kDa) and vitamin B12 (Mr = 
1.35 kDa). 
 
Protein-containing fractions were concentrated to 12 mg·ml-1 with a Slide-A-Lyzer 
Dialysis Cassette (3500 MWCO, Thermoscientific, Massachusetts, USA) and an 
SDS-PAGE was run, to verify its purity. Protein concentration was determined by 
measuring the absorbance at 280 nm using the calculated extinction coefficient of 
9970 M-1·cm-1 (http://web.expasy.org/protparam). 
 
C-GRP-C 
A HiTrap (GE Healthcare, Little Chalfont, UK) column binds with specificity to the 
Poly-Histidine tail in expression vectors. This column was set in an ÄKTA Prime 
system (GE Healthcare, Little Chalfont, UK), at flow rate 0.4 ml·min-1 and 277 K, 
with 5 ml NiSO4 and equilibrated with the same lysis buffer used in the previous 
step. The protein with the pET28-PP was run through with a buffer with 50 mM 
Tris-HCl pH 7.5, 200 mM NaCl and a gradient of imidazole ranging from 10 mM to 
500 mM for elution of the protein of interest only.  
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Both elutions were run separately in a Superdex 75 (GE Healthcare, Little Chalfont, 
UK) with buffer 20 mM Tris-HCl pH 7.5, 100 mM NaCl and 2 mM DTT. The col-
umn was calibrated as described in the previous section. The protein with the pET28-
PP showed a peak at the C-GPR-C M.W. 16 kDa. The Poly-Histidine tag was re-
moved by incubation and dialysis with protease 3C, further purification was made 
by affinity chromatography and molecular exclusion chromatography. The final 
samples were concentrated to 16 mg·ml-1 with a Slide-A-Lyzer Dialysis Cassette 
(3500 MWCO, Thermoscientific, Massachusetts, USA) and an SDS-PAGE was run, 
to verify its purity. Protein concentration was determined by measuring the absorb-
ance at 280 nm using the calculated extinction coefficient of 8730 M-1·cm-1 
(http://web.expasy.org/protparam). 
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2. PROTEIN CRYSTALLIZATION 
 
“Finding the exact conditions to produce good crystals of a specific protein often 
requires many careful trials, and is perhaps more art than science” Gale Rhodes in 
Crystallography Made Crystal Clear. 
 
2.1 Nucleation and crystal growth 
 Protein crystal growth implies at least 
two major stages: formation of an ini-
tial solid object, or nucleus, in the 
original phase, and the nucleus grow-
ing. Crystal growth is a first order 
phase transition in which there must 
be (Fig 6): (i) a crystalline surface, 
separating the crystal from the original 
phase, (ii) a metastable zone around 
the point of thermodynamic equilib-
rium, and (iii) a nucleation barrier, 
preventing further nucleation in any 
other part of the original phase. The 
crystallization process of a biomacro-
molecule requires lowering the solu-
bility at a slow and constant rate within an adequate time frame. In the labile region 
of the curve, crystal nucleation and growth compete, whereas in the metastable re-
gion only crystal growth appears. In the unsaturated region the crystals dissolve 
(Mendoza and Moreno, 2015). 
 
Practically, the four main stages of protein crystallization are (Fig 7):  
(a) phase separation.- marks the co-existence of a dense liquid in a less dense 
one. 
(b) precipitation and nucleation.- the phase separation favors the ordering of the 
protein molecules inside the dense droplets and the generation of nucleation 
sites. 
(c) crystallization.- around the nuclei formed, the crystals grow in proportion 
with the protein’s density increase and the solution’s density gradual reduc-
tion. 
(d) crystal growth.- if the process is to continue, that is, the density equilibrium 
is not broken, the protein crystals are susceptible to keep growing in size.  
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Fig 6. Protein nucleation and crystal growth. 
Protein solutions need to reach supersaturation to 
create crystalline nucleus from which crystals will 
grow in the metastable zone. 
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2.2 Protein solubility 
Protein solubility can be influenced by several factors, such as ionic strength, pH and 
counter ions, temperature and organic solvents. In aqueous solution, each ion is sur-
rounded by an atmosphere of counter ions; this atmosphere influences the interac-
tions of the ion with water molecules and hence the solubility. As for the pH, the 
more soluble a protein, the larger is its net charge, with the minimum solubility being 
found at the isoelectric point. The packing in solid state (in the crystal) is favored 
when electrostatic interactions happen without the accumulation of a net charge in 
high energy. Protein solubility is temperature-dependent for in the solution energy 
equation, G0 = H – TS, the entropy term has an increasing influence with in-
creasing temperature (Messerschmidt 2007). 
 
GAL-3[N VII-IX] 
Screening for crystals was conducted in 96-well sitting-drop plates (Swissci MRC, 
Molecular Dimensions, Suffolk, England) at 295 K using a Cartesian Honeybee Sys-
tem (Genomic Solutions, Irvine, USA) and the JBScreen Classic (Jena Bioscience, 
Jena, Germany), Wizard Classics I–III (Emerald Bio, Bainbridge Island, USA) and 
Fig 7. Stages of protein crystallization. (a) Phase separation, (b) precipitation and nucleation, (c) 
crystallization, (d) crystal growth, as seen through a magnifying glass on the crystallization plates. 
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Index (Hampton Research, Aliso Viejo, USA) commercial kits. The drops were 0.4 
l in volume, consisting of 0.2 l protein solution and 0.2 l precipitant, equilibrated 
against 50 l reservoir solution.  
 
Further attempts to optimize the initial crystallization conditions were performed us-
ing optimization screens prepared with a Freedom EVO liquid-handling robot 
(TECAN, Männedorf, Switzerland). The selected conditions were: 
(i) 18%(w/v) PEG 8000, 100 mM Tris–HCl pH 8.5, 200 mM Li2SO4; and 
(ii) 22%(w/v) PEG 8000, 100 mM MES pH 6.5, 200 mM (NH4)2SO4.  
Different grids varying PEG molecular weight (PEG 6000, PEG 8000 and PEG 
10000), PEG concentration (15–30%) and pH from 6.0 (100 mM MES) to 9.0 (100 
mM Tris–HCl) were prepared, with Li2SO4 as additive. Crystals were cryo-protected 
with the reservoir solution supplemented with 12.5%(w/v) PEG400, mounted on ny-
lon loops and flash-cooled in liquid nitrogen for X-ray data collection. 
 
C-GRP-C 
Systematic screening for conditions to crystallize C-GRP-C was performed in 96-
well sitting drop plates (Swissci MRC, Suffolk, England) at 295 K using a Cartesian 
Honeybee system (Genomic Solutions, Irvine, USA) and commercially available 96-
well kits: JBScreen Classic (Jena Bioscience™), Wizard Classic Screen I–III (Emer- 
ald Bio™) and Index Crystal Screen (Hampton Research™). The drops were 0.4 μL 
in volume, a mixture of 0.2 μL of the protein solution and 0.2 μL of precipitant, 
equilibrated against 50 μL of the reservoir solution. Diffracting crystals grew after a 
couple of weeks in the presence of 2.0 M (NH4)2SO4, 100 mM MES (pH 6.5) and 
5% (w/v) PEG 400. Crystals were cryo-protected with the reservoir solution supple-
mented with a 1.0 M sodium malonate solution, mounted on nylon loops and flash-
cooled in liquid nitrogen for X-ray data collection. 
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3. PROTEIN CRYSTALLOGRAPHY 
3.1 Principles of crystalline symmetry 
 
“The characteristic symmetry of a physicochemical phenomenon is the highest 
symmetry compatible with the phenomenon existence” Pierre Curie. 
 
In the experiment performed by Friedrich and Knipping in 1912, using CuSO4, X-
rays produced with a tungstene anti-cathode and a photographic plaque as detector, 
an interference pattern was observed that demonstrated properties like (Friedrich et 
al 1912): 
- crystalline solids have a periodic arrangement; 
- X-rays wavelengths have similar dimensions to the interatomic distances. 
 
Spatial relations between the constituents of a crystalline solid occur at short and 
long ranges, hence influenced by both the physical and chemical properties of the 
crystal. The basic repeating unit from which the crystal is constructed is the unit cell 
(Cowtan 2001; Mendoza and Moreno 2015). For each crystal, a reciprocal lattice of 
the X-ray scattering can be constructed, which is useful when interpreting the atoms 
positions (see Ewald’s sphere below). 
 
3.2. Solvent content in crystals 
Crystals solvent content was broadly discussed by Matthews et al (1968), who es-
tablished for the first time how to quantify water content inside a protein crystal. The 
Matthews volume (VM) is defined by the crystal unit cell volume radius over the 
molecular weight of the protein. Thus, VM represents the crystal volume per mass 
unit of molecular protein, which is practically independent from the asymmetric unit 
volume and mainly dependent on the solvent content. The common values for VM 
generally range from 1.6 Å3·Da-1 to 3.5 Å3·Da-1 (Messerschmidt 2007). 
 
3.3. Synchrotron radiation 
As electrically charged particles such as electrons or positrons of high energy are 
kept under the influence of magnetic fields and travel in a pseudocircular trajectory, 
synchrotron radiation is emitted. In the practice, these particles are injected into a 
storage ring directly from a linear accelerator or through a booster ring, and circulate 
in a high vacuum for several hours at a relative energy. In order to keep the bunched 
particles traveling in a near-circular path, an arrangement of bending magnets is set 
up around the storage ring. As the particle beam traverses each magnet, the path of 
the beam is altered, and synchrotron radiation is emitted. The loss of energy of the 
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particle beam is compensated by an oscillating radiofrequency electric field at each 
cycle. Synchrotron radiation is highly polarized, and can be channeled through dif-
ferent beamlines for use in research (Messerschmidt 2007).  
 
3.4. Data collection 
The primary beam in a synchrotron radiation facility leaves the X-ray source and 
passes the X-ray optics collimator. The crystal is mounted on a goniometer head 
capable of perform spatial movements around the center of the beam source, either 
in a quartz capillary or in a flash-cooled cryo-loop. The X-ray detector, which regis-
ters the diffracted intensities, is mounted on a device which allows the translation 
and rotation of the detector. A piece of lead is placed in the path of the primary beam 
just behind the crystal to prevent damage to the detector and superfluous gas scatter-
ing. The X-rays are scattered from every point in the crystal, with a strength in pro-
portion to the concentration of electrons at that point. An X-ray reflection is gener-
ated when a point of the reciprocal lattice lies on a sphere of radius 1/, whose origin 
is 1/ away from the origin of the reciprocal lattice in the direction of the primary 
beam. The direction of such a diffracted beam is along the center’s connection of the 
so-called Ewald sphere (radius 1/), and the intersection of the reciprocal lattice 
point on this sphere (Fig 8). The apparent reciprocal lattice extends only to a given 
radius which defines the resolution sphere.  
 
 
Fig 8. The Ewald sphere for reciprocal lattices. The angle 2θ = 0–180º. The diffracted ray can go in 
any direction in three dimensions, the vector representing it can have its tip anywhere at the surface of 
a sphere with a radius of 1/λ. The diffracted ray has its base at the center of the sphere, considered the 
origin of the crystal. But the origin of the reciprocal space has to be at the point where the direct beam 
exits the sphere (Drenth 1994). 
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(3.5.1) 
(3.5.5) 
(3.5.2) 
(3.5.3) 
(3.5.4) 
Each individual exposure is processed and the data stored electronically in a com-
puter. These raw data images are evaluated subsequently to provide the intensities 
and geometric reference values (indices) for each collected intensity (Cowtan 2001; 
Messerschmidt 2007).  
 
3.5. Rational mathematical representation of X-ray diffraction 
The simplest periodic process in time (oscillation) is given mathematically by the 
sine or cosine function. If the process is recurring v times per second, it is written as: 
 
𝑢(𝑡) = 𝐴 sin 2𝜋𝜈𝑡    or    𝑢(𝑡) = 𝐴 cos 2𝜋𝜈𝑡 
 
where A is the amplitude and  is the frequency. The actual value of 2t is called 
the phase angle, and this determines the momentary state, i.e. the phase. 
 
Computation becomes much easier if the imaginary exponential function is used in-
stead of the cumbersome trigonometric functions.The trigonometric functions are 
related to the exponential function by Euler’s formula: 
 
exp 2𝜋𝑖𝜈𝑡 = cos 2𝜋𝜈𝑡 + 𝑖 sin 2 𝜈𝜋𝑡 
 
This representation leads to:   
𝑧 = 𝐴 exp 2𝜋𝑖𝜈𝑡 
 
where z is a complex number, the representation point of which rotates on a circle of 
radius A with an angular velocity of 2. The projections onto the real and imaginary 
axis are: 
 
𝑥 = Re(𝑧) = 𝐴 cos 2𝜋𝜈𝑡;      𝑦 = Im(𝑧) = 𝐴 sin 2𝜋𝜈𝑡 
 
An equation between complex numbers means that both the real and the imaginary 
part of each side fulfill the equation. Thus, the real and the imaginary parts of the 
equation can be taken as the physical meaning of the equation.  
 
The square of the amplitude A2 is important and can be obtained in the complex 
computation by multiplying the oscillation magnitude 𝑧 by its complex conjugated 
value 𝑧̅: 
𝐴2  =  𝑧𝑧̅ 
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(3.6.1) 
(3.6.2) 
(3.6.3) 
3.6. X-ray scattering by a crystal 
As X-rays are electromagnetic waves, Maxwell’s equations are valid in the physical 
process of X-ray scattering by atoms. X-ray propagate in a vacuum with the velocity 
of light; they are transversal waves with the electric field component E and the mag-
netic field component H, respectively, oscillating perpendiculary to the direction of 
propagation and perpendicularly to each other. For a three-dimensional crystal, the 
unit cell is spanned by the unit cell vectors a, b and c, and is repeated periodically 
by the corresponding vector shifts r = 𝑚1a + 𝑚2b + 𝑚3c, being 𝑚1, 𝑚2, 𝑚3 inte-
gers, in the respective spatial direction. The scattering of the X-ray waves by a crystal 
can then be written:  
 
E(S) =  −
𝜀2
𝑐2𝜇
1
𝑟0
 √
1 + cos2 2𝜃
2
E0
𝑒F(S) ∑ exp 2𝜋𝑖𝑚1(aS)
𝑁1
𝑚1
∑ exp 2𝜋𝑖𝑚2(bS)
𝑁2
𝑚2
 
∑ exp 2𝜋𝑖𝑚1(cS)
𝑁3
𝑚3
 
 
The three sum terms are geometric series which can be easily calculated. The inten-
sity can be obtained by squaring E(S). The squares of the complex magnitudes are 
established by multiplying it with its complex conjugate. Carrying out these multi-
plications reveales concise expressions and the intensity I(S):  
 
 I(S) = −
𝜀4
𝑐4𝜇2
1
𝑟0
2  (
1 + cos2 2𝜃
2
) 𝐼0𝐹
2 (S)
sin2 𝜋 𝑁1(aS)
sin2 𝜋 (aS)
sin2 𝜋 𝑁2(bS)
sin2 𝜋 (bS)
  
 
sin2 𝜋 𝑁3(cS)
sin2 𝜋 (cS)
 
 
The last three factors are known as interference function 𝐼𝐹. The function has maxima 
of 𝑁1
2𝑁2
2𝑁3
2 when the three subsequent conditions are fulfilled (h, k and l being the 
corresponding diffraction intensities at the reciprocal lattice points): 
 
aS = ℎ;  bS = 𝑘;  cS = 𝑙 
 
These conditions are known as Laue equations. If the constant magnitudes in Eq 
(3.6.2) are neglected, the equation for the total scattered wave for a three-dimen-
sional crystal with a unit cell containing N atoms is: 
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(3.6.5) 
(3.6.6) 
(3.7.1) 
(3.7.2) 
(3.7.3) 
(3.6.4) F(S) = ∑ 𝑓𝑗 exp 2𝜋𝑖𝐫𝑗𝐒
𝑁
𝑗=1
 
 
with 𝐫𝑗𝐒 = ℎ𝑥𝑗 + 𝑘𝑦𝑗 + 𝑙𝑧𝑗 from Laue’s equation, and: 
 
𝐅(ℎ𝑘𝑙) = ∑ exp 2𝜋𝑖(ℎ𝑥𝑗 + 𝑘𝑦𝑗 + 𝑙𝑧𝑗)
𝑁
𝑗=1
=  |𝐅(ℎ𝑘𝑙)| exp 𝑖𝑎(ℎ𝑘𝑙) 
 
with |F(ℎ𝑘𝑙)| being the amplitude and 𝑎 being the phase angle. The intensity of the 
scattered wave is obtained as the structure factor F(ℎ𝑘𝑙) multiplied by its complex 
conjugate value, according to this equation: 
 
𝐼(ℎ𝑘𝑙) =  F(ℎ𝑘𝑙)F*(ℎ𝑘𝑙) = |F(ℎ𝑘𝑙)|2 
 
3.7. The Patterson function and Friedel’s law 
The measured X-ray intensities are proportional to the square of the absolute value 
of the structure factor according to Eq (3.6.6). It is possible to use the intensities 
directly to calculate a function that contains structural information. By calculating a 
convolution of the electron density with itself, Patterson (1934) showed that this is 
just the Fourier transform (FT) of the intensities:  
 
𝑃(𝐮) = ∫ 𝜌(𝐱)𝜌(𝐱 + 𝐮)𝑑𝐱
0
𝑉𝑐𝑒𝑙𝑙
 
 
In the case of real atomic scattering factors f, the diffraction intensities are centro-
symmetric according to Friedel’s law: 
 
𝐼(ℎ𝑘𝑙) = 𝐼(ℎ̅?̅?𝑙)̅ 
 
From Eqs (3.6.4), (3.7.1) and (3.7.2) i.e., Friedel’s law, it is possible to obtain the 
following equation:  
F(S) = ∑ 𝑓𝑗 exp 2𝜋𝑖𝐫𝑗𝐒
𝑁
𝑗=1
= ∫ 𝜌(x) exp 2𝜋𝑖𝐫𝐒d𝜈
0
𝑉𝑐𝑒𝑙𝑙
 
 
that shows the equation for the structure factor is the FT of the electron density 𝜌(𝐫) 
(Messerschmidt 2007). 
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3.8 Software for crystallographic resolution 
On these mathematical basis, several specialized softwares have been developed for 
resolving protein structures by X-ray crystallography. The programmers’ web pages 
contain thourough information on both the developing and the usage of their crystal-
lography software packages (CCP4: Evans and Murshudov 2013; Phenix: Adams 
et al 2010; XDS: Kabsch 2010; Coot: Emsley et al 2010; PyMol: DeLano 2012). 
 
Image processing with XDS can be done in Unix or Mac OS platforms, and provides 
important data such as the total number of unique reflections, the resolution range, 
the unit cell dimensions (a, b, c; ) and the symmetry of the crystal lattice. This 
software’s output is the first step to decide on the quality of the data (Kabsch 2010). 
The reflections’ scaling is done with the program Aimless (Karplus and Diederichs 
2012; Evans 2011), from the CCP4 software package (Evans and Murshudov 2013), 
which scales the diffraction data merging intensities, and alternatively with scaled 
but unmerged observations, giving out results in terms of the Fourier transform co-
efficients. 
 
From the X-ray diffraction data, the amplitudes are derived but not the phases (Cow-
tan 2001). If both parameters were known, the protein’s electronic density could be 
obtained by simply applying the inverse Fourier transform to the experimental struc-
ture factors. Thus, it is necessary to use an alternative method that allows the esti-
mation of the structure phases factors in order to calculate the experimental elec-
tronic density: this is known as the phase problem. For the calculation of the phases, 
different approaches have been used. In this work, the method used was that of mo-
lecular replacement, with Phenix (Adams et al 2010). 
 
Molecular replacement 
When the molecule under study is reasonably similar to another molecule whose 
structure is already known, the molecular replacement method allows phases to be 
obtained from the known structure. This is done by calculation of the rotation and 
translation functions: the known molecule is first rotated in three dimensions, and 
for each orientation, structure factors are calculated from the model. The agreement 
between the calculated structure factors and the observed values from the diffraction 
experiment is used to identify the orientation of the known molecule that most 
closely matches that of the unknown molecule in the crystal. Next, the oriented 
model is placed at every possible position in the unit cell, and again the agreement 
of the structure factors is used to identify the correct translation (Adams et al 2010).  
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(3.8.1) 
Crystallographic refinement 
Once phase estimates (or phase probability distributions) are available, an initial 
electron density map may be calculated. At this point it is possible to apply chemical 
knowledge to improve this map and the phases. The electron density in regions of 
disordered solvent does not show identifiable features, so the electron density map 
can be improved by flattening the solvent and, furthermore, sharpening the features 
inside the protein region. Once the map has been modified, it is used to calculate a 
new set of structure factors and phases. Averaging the density between these copies 
also reduces the noise level in the map. All these calculation may be repeated over 
several cycles (Cowtan 2001). 
 
Phenix software suite is a highly automated system for macromolecular structure 
determination that can rapidly arrive at an initial partial model of a structure, through 
the general formula (3.7.3), which numerically resolved, is the discrete Fourier trans-
form of the electronic density in a sphere of radius r ~2 Å around each atom. This 
achievement has been made possible by the development of new algorithms for 
structure determination, such as maximum-likelihood molecular replacement 
(Phaser), automated macromolecular refinement (phenix.refine), and iterative 
model-building. Phenix builds upon Python, the Boost.Python Library and C++ to 
provide an environment for automation and scientific computing. Final evaluation of 
the refinement iterations quality is made by calculating the R-factor, which estab-
lishes the relative difference between the observed structure factors (Fobs) and the 
calculated structure factors for a theoretical model (Fcalc), and it is determined with 
the following equation (Adams et al 2010): 
 
𝑅 =  
∑ ℎ𝑘𝑙[[Fobs(ℎ𝑘𝑙)] − [Fcalc(ℎ𝑘𝑙)]]
∑ ℎ𝑘𝑙[Fobs(ℎ𝑘𝑙)]
 
 
Visualization and manual correction of the generated map around the amino acid 
structure is done with the software Coot (Emsley et al 2010), a graphical interface 
that also allows the calculation of electronic density, atypical values in stereochem-
ical parameteres, distances and bond angles, and correspondence with Ramachan-
dran values for the dihedral angles of the protein residues (Ramachandran and 
Sasisekharan 1968). 
 
3.9. Principles of the self-rotation function 
Proteins frequently crystallize with more than one copy of the molecule in one unit 
cell, or asymmetric unit in the case of crystals with internal symmetry. The self-
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(3.9.2) 
rotation function can be used to determine the orientation and order of local sym-
metry, an information that it is also needed for refinement. Multi-subunit proteins 
often exhibit non-crystallographic symmetry relating the subunits. The Patterson 
function contains a set of peaks representing intramolecular vectors (self-vectors) for 
each molecular orientation found in the crystallographic cell. These peaks are dis-
tributed around the Patterson origin within a volume of double the molecular diam-
eter, differentiating them from the intermolecular vectors (cross-vectors) which, de-
pending on the molecular packing, can occur anywhere in the Patterson function. 
The self-rotation function R(C) is the auto-correlation function of the native Patter-
son, P(x), with a rotated version of itself: 
 
𝑅(𝐶) = ∫ 𝑃(𝐱)𝑃(𝐂(𝐱))d𝑥 
 
where C(x) is the three-dimensional rotation matrix that relates the rotated coordi-
nate system to the stationary one, and: 
 
𝑃(𝑥, 𝑦, 𝑧) =
1
𝑉
∑ ∑ ∑|F|2 cos 2𝜋(ℎ𝑥 + 𝑘𝑦 + 𝑙𝑧)
𝑙𝑘ℎ
 
 
The R(C) function will have a maximum of orientations where two molecules in the 
unit cell superimpose.  
 
Visualization is easier with the spherical polar angle convention that accomplishes 
any rotation by an appropriate spin  about a properly chosen axis, specified by two 
angles  and . A molecular n-fold rotation will be found in this system in a = 
360º/n section. Thus, self-rotation function peaks corresponding to a two-fold axis 
occur in the  = 180º, a three-fold in the = 120º section, and so forth (Rossmann 
and Blow 1962; Cowtan 2001). 
 
GAL-3[N VII-IX]  
X-ray diffraction data were collected using a PILATUS 6M detector (Dectris) on the 
BL13 XALOC beamline at the ALBA synchrotron. Crystals were rotated with an 
oscillation angle of 0.5º and an exposure time of 0.5 s per image, and had a resolution 
of 3.3 Å. The data were processed using XDS (Kabsch 2010) and integrated and 
scaled using Aimless (Evans et al 2011; Evans & Murshudov 2013).  
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New crystals were obtained in conditions of 18%(w/v) PEG 8000, 100 mM Tris–
HCl pH 8.5, 200 mM Li2SO4 and data collection showed a resolution of 2.2 Å. The 
structure was solved by molecular replacement using Phaser (Adams et al 2010) and 
the Gal-3 CRD-only structure (PDBID: 1A3K; Seetharaman et al 1998) as a search 
model, and the 3.3 Å resolution structure, expecting an occupancy of eight to twelve 
molecules in one unit cell. The initial model was first refined with phenix.refine (Ad-
ams et al 2010) and alternating manual building with Coot (Emsley et al 2010). The 
final model was obtained by repetitive cycles of refinement; solvent molecules, lac-
tose and sulfate molecules were added automatically and inspected visually for 
chemically plausible positions. The MolProbity software was used to check the pro-
tein was in allowed regions of the Ramachandran plot (http://molprobity.bio-
chem.duke.edu/). Data collection statistics are shown in Table 1 (see Results). Struc-
tural figures were drawn with PyMOL (DeLano 2012).  
 
C-GRP-C 
X-ray diffraction data were collected on a single crystal using a Pilatus 6M detector 
at the BL13 XALOC beamline at the ALBA synchrotron. A total of 960 rotation 
images were collected with an oscillation angle of 0.25°. The resulting data set was 
processed using XDS (Diederichs and Karplus 1997; Kabsch 2010) and scaled using 
Aimless (Evans 2011; Evans and Murshudov 2013). The structure was solved by 
molecular replacement using Phaser (Adams et al 2010) and the human GRP struc-
ture (PDBID: 3B9C; Zhou et al 2008) as a search model. The initial model was first 
refined with Refmac5 (Evans and Murshudov 2013), alternating manual building 
with Coot (Emsley et al 2010). The final model was obtained by repetitive cycles of 
refinement using Phenix (Adams et al 2010). Solvent molecules were added auto-
matically and inspected visually for chemically plausible positions. The placement 
of PEG, ethylene glycol and sulfate molecules was done using Coot (Emsley et al 
2010). The MolProbity software was used to check the protein was in allowed re-
gions of the Ramachandran plot (http://molprobity.biochem.duke.edu/). Data collec-
tion statistics are shown in Table 2 (see Results). Structural figures were drawn with 
PyMOL (De Lano 2012). 
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(4.1.1) 
4. PROTEIN BIOPHYSICAL CHARACTERIZATION 
4.1. Small-Angle X-ray Scattering 
A complementary technique for X-ray diffraction is the so-called Small-Angle X-
ray Scattering (SAXS), which provides structural information about the size, shape 
and flexibility of a molecule in solution (Putnam et al 2007; Grant et al 2015). 
Though SAXS data resolution is semi-automatized through specialized software, the 
major challenge data acquisition presents is radiation damage. Ionizing radiation can 
cause biomacromolecules to form high-molecular-weight oligomers through cross-
linking reactions, disulfide bond formation and/or other hydrophobic/electrostatic 
interactions, all of which produce changes in the protein’s tertiary structure (Franke 
et al 2012). These effects are reflected in parameters changes such as the Guinier 
plot (Guinier and Foumet 1955), the radius of gyration (Rg) and the maximum parti-
cle dimension (Dmax) (Le Maire et al 1990). 
 
The final Guinier plot and the calculated Rg for the global size of a molecule are 
determined through a somewhat subjective interpretation of what it is an acceptable 
linear region. The Guinier plot linearity is an important pre-requisite to ensure the 
sample’s monodispersion (Jacques and Trewhella 2010). The assessment of these 
values is automatized in the software AutoRg (Petoukhov et al 2012), that determines 
the linearity and calculates Rg with the formula:  
 
𝑅𝑔 = √
∫ 𝑟2𝑃(𝒓)d𝑟
𝐷𝑚𝑎𝑥
0
2 ∫ 𝑃(𝒓)d𝑟
𝐷𝑚𝑎𝑥
0
 
 
where Dmax is the maximum particle dimension, r is the interatomic distance, and 
P(r) is the pair distribution function (Putnam et al 2007; Petoukhov et al 2012). Dmax 
calculation can then be done from the distribution function P(r) taking the intensity 
at angle zero (I(0)). In the practice, data cannot be collected to the infinite so the final 
calculation of Dmax is made using an indirect method of the Fourier transform, with 
the software GNOM, finally averaging the calculations with the software 
DAMAVER (Svergun 1992). 
 
GAL-3[N VII-IX] 
Using the same procedure for sample purification in Section 1.2.2 of Material and 
Methods, new Gal-3[N VII-IX] samples were purified and prepared at a series of 
concentrations of 3, 4, 6, 8 and 10 mg·ml-1, and Gal-3 full-length (Gal-3FL) samples 
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were purified and prepared at a series of concentrations of 2, 4, 6 and 8 mg·ml-1. 
SAXS data on Gal-3FL and Gal-3[N VII-IX] were collected on the BM29 beamline 
at the European Synchrotron Radiation Facility (ESRF, Grenoble, France) using the 
BioSAXS robot and a Pilatus 1M detector (Dectris AG, Baden-Daettwil, Switzer-
land) with synchrotron radiation at a wavelength λ=0.1 nm.  
 
For each measurement, ten frames were obtained at 1 s exposures of an 80 µl sample 
flowing continuously through a 1 mm diameter capillary during X-ray exposure, and 
protein-free buffer processed as control. The scattering images were spherically av-
eraged and buffer’s scattering intensities subtracted using software from the ESRF 
(Grenoble, France). The Rg was calculated with GNOM, which also gives the dis-
tance distribution function P(r) and the Dmax. Bead models were obtained using the 
ATSAS software package. Each model was produced from 20 runs of DAMMIN 
that were combined and filtered to produce an averaged model using DAMAVER  
(Svergun 1992).  
 
C-GRP-C 
C-GRP-C samples precipitated in (NH4)2SO4 were set for overnight dialysis in PBS 
1X and BME. Purification was made using a molecular exclusion chromatography 
column Superdex 75 with and elution buffer containing 20 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA and 1 mM DTT. Purified C-GRP-C samples were pre-
pared at a series of concentrations of 2, 4, 6 and 8 mg·ml-1. SAXS data on C-GRP-C 
were collected on the BM29 beamline at the European Synchrotron Radiation Facil-
ity (ESRF, Grenoble, France) using the BioSAXS robot and a Pilatus 1M detector 
(Dectris AG, Baden-Daettwil, Switzerland) with synchrotron radiation at a wave-
length λ = 0.1 nm.  
 
For each measurement, ten frames were obtained at 1 s exposures of a 100 µL sample 
flowing continuously through a 1 mm diameter capillary during X-ray exposure, and 
protein-free buffer processed as control. The scattering images were spherically av-
eraged and buffer scattering intensities subtracted. The Rg, P(r) and Dmax were cal-
culated with GNOM, Bead models were obtained using the ATSAS software pack-
age. Each model was produced from 20 runs of DAMMIN that were combined and 
filtered to produce an averaged model using DAMAVER (Svergun 1992).  
 
4.2. Analytical ultracentrifugation 
Analytical ultracentrifugation (AUC) is a versatile and powerful method for the 
quantitave analysis of macromolecules in solution. AUC has broad applications for 
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(4.2.1) 
the study of biomacromolecules in a wide range of solvents and over a wide range 
of solute concentrations. Using specialized sample cells and modern analysis soft-
ware, researchers can use sedimentation velocity to determine the homogeneity of a 
sample and define whether it undergoes concentration-dependent association reac-
tions, determining the nature of the species present in solution and their interactions. 
 
When the centrifugal force is sufficiently small, an equilibrium concentration distri-
bution of macromolecules is obtained throughout a cell where the flux due to sedi-
mentation is exactly balanced by the flux due to diffusion. The shape of this concen-
tration gradient can be derived using a variety of approaches. For an ideal single non-
interacting species, the equilibrium radial concentration gradient, c(r), is given by: 
 
𝑐(𝑠) = 𝑐0 exp [
𝑀𝑏𝜔
2
𝑅𝑇
(
𝑠2 − 𝑠0
2
2
)] = 𝑐0 exp [𝜎 (
𝑠2 − 𝑠0
2
2
)] 
 
where c0 is the concentration at an arbitrary reference distance s0. The term Mb2/RT 
is often referred to as the reduced molecular weight, . Sedimentation equilibrium 
experiments provide a very accurate way to determine M and consequently the oli-
gomeric state of biomolecules in solution. Deviations from the simple exponential 
behavior described by Eq (4.2.1) can result from the presence of either multiple non-
interacting macromolecular species, or thermodynamic non-ideality (Cole et al 
2008). 
 
C-GRP-C 
C-GRP-C solutions of 0.2, 1 and 2 mg·ml-1 were prepared and cleared by a centrif-
ugation step for 10 mins at 16,000 g. Sedimentation velocity AUC experiments were 
set at 277 K in an Optima XL-I instrument (Beckman Coulter, Krefeld, Germany) 
equipped with an AN50-Ti rotor at 48 krpm. Differential sedimentation coefficients 
were calculated by least-squares boundary modeling of the experimental data using 
the c(s) method implemented in the program SedFit version 14.7 (Schuck et al 2015).
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RESULTS 
 
                                                                                                                             GAL-3[N VII-IX] 
Protein purification 
 
Galectins display high-affinity binding to lactose, a property that can be used to pu-
rify them by affinity chromatography on β-galactoside supports. A suspension of 
human Gal-3 [N VII-IX] in ammonium sulfate was set for dialysis overnight, and 
afterwards bound to a lactosylated Sepharose 4B column (as described in Material 
and Methods). After loading, the column was washed with approximately 5 column 
volumes of washing buffer (20 mM PBS, pH 7.2, 150 mM NaCl and 4 mM BME) 
until a stable baseline was reached. The protein was then eluted with buffer contain-
ing 200 mM lactose and 4 mM BME.  
 
Controls for purity were performed by standard SDS-PAGE (Fig 9). The lack of 
protein in the flow-through and wash fractions underscores the optimal binding of 
the protein to the lactose matrix.  
 
In order to remove any other contaminant, a further purification of the sample was 
carried out through a size exclusion chromatography (HiPrep 16/60 Sephacryl S-
100) on an ÄKTA Prime equipment. The last elution peak of the chromatogram cor-
responding with the appropriate size (21 kDa) of the protein (lanes 17 to 21), 
showed a pure protein as could be seen by SDS-PAGE (Fig 10). These fractions 
were pooled together, concentrated with a Slide-A-Lyzer Dialysis Cassette (3500 
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Fig 9. SDS-PAGE gel of hGal-3 [N VII-IX]. Mo-
lecular weight marker (left), dialysis (lane 1), flow-
through (lane 2), wash fraction (lane 3) and elution 
fraction (lane 4). 
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MWCO, Thermo Scientific, Rockford, USA) to different concentrations of 3, 4, 6, 8 
and 10 mg·ml-1 and stored at 193 K for SAXS experiments, and to 16 mg·ml-1 for 
crystallization experiments. 
 
 
The purification protocol for full-length Gal-3 was similar to the previous one for 
the Gal-3[N VII-IX] variant.  
Fig 10. Size exclusion chromatography, Gal-3[N VII-IX] a) UV chromatogram, b)SDS-
PAGE. Two marked peaks were found in the size exclusion chromatography, and fractions were 
collected and run through an SDS-PAGE to test their purity. The second peak fractions showed 
bands with high purity in the molecular weight of Gal-3[N VII-IX] 21 kDa. 
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X-ray diffraction data resolution 
Crystals of Gal-3[N VII-IX] grew to a size 
of 0.05 x 0.05 x 0.03 mm plates (Fig 11) in 
the conditions: (i) 18%(w/v) PEG 8000, 100 
mM Tris–HCl pH 8.5, 200 mM Li2SO4; and 
(ii) 22%(w/v) PEG 8000, 100 mM MES pH 
6.5, 200 mM (NH4)2SO4. The crystals were 
cryoprotected, stored in a dry-shipping 
Dewar and taken to the light source line 
XALOC (ALBA synchrotron, Cerdanyola 
del Vallès, Spain) for X-ray diffraction data 
collection. This batch of crystals diffracted 
to a resolution of 3.3 Å (Fig 12), from 
which some information was obtained. For 
instance, data analysis revealed that crystals 
belonged to the orthorhombic space group P212121, as indicated by systematic ab-
sences. Data processing showed signs of radiation damage after exposure ( = 200º), 
thus limiting the resolution value to ensure better quality. However, at 3.3 Å resolu-
tion, a noticeable signal was observed as indicated by the value I/(I) ~ 10.1 (overall) 
and 2.8 (last resolution shell), with 99.8% completeness and an Rmerge of 0.169.  
Fig 11. Crystals of Gal-3[N VII-IX]. Image 
of grown crystals seen under polarization of 
the light. 
Fig 12. X-ray diffraction of Gal-3[N VII-IX]. The X-ray diffraction image is at  = 60º 
with a resolution ring at 3.3 Å. 
3.3 Å 
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Also, a new feature appeared for this structure that had not been reported for Gal-3 
CRD crystal structures: the protein is forming oligomers. A method to quantitatively 
determine the presence of more than one protein molecule in a unit cell is through 
the solvent content determination as described in the previous section. The Matthews 
coefficient for Gal-3[N VII-IX] was indicative of the presence of between six (VM = 
4.28 Å3Da-1, solvent content 71.04%) and twelve (VM = 2.14 Å3Da-1, solvent content 
42.08%) molecules in the asymmetric unit, being difficult to narrow down the actual 
number of molecules. To facilitate this task, Patterson self-rotation function analysis 
was performed using MOLREP (Vagin and Teplyakov 2010). This analysis showed 
peaks corresponding to a 4-fold axis (with º parallel to the z axis, and two 2-
fold axes (with  = 180º) in the xy plane (Fig 13). These results are summarized in 
Table 1 and constituted the first published information on Gal-3 with a section of 
the N-PG and its oligomerization in crystal form (Flores-Ibarra et al 2015, see Pub-
lications). 
 
The structure was then solved by molecular replacement using Phaser (Adams et al 
2010) and the coordinates of the human Gal-3 CRD (PDBID: 1A3K, Seetharaman 
et al 1998) as the search probe. The initial rotational and translational searches iden-
tified eight monomers in the asymmetric unit with values of TFZ = 41.3 and LLG = 
6485. This partial solution was then refined using phenix.refine (Adams et al 2010) 
along with manual building in Coot (Emsley et al 2010). In Fig 14 is depicted the 
Fig 13. Self-rotation function of Gal-3[N VII-IX] crystals. These results had an integration 
radius of 30 Å and data was between 15 and 4 Å resolution. The crystallographic a axis is along 
 = 0º,  = 90º and the c* axis is perpendicular to the plane of the figure. 
BACK TO OUTLINE 
49 
 
density map (blue density) for the first round of molecular replacement for Gal-3[N 
VII-IX], where eight molecules accommodate (ribbon representation, each monomer 
in a different color), as well as strong positive electronic density areas (green density, 
white arrows), indicating the presence of more subunits. Moreover, in agreement 
with the Matthew’s coefficient and the self-rotation function, it became clear that the 
structure had a non-crystallographic symmetry in which the basic unit in the crystal 
was a tetramer, which makes it possible then to obtain either an octamer or a do-
decamer in the unit cell. With this information it was decided to run a new search 
and refinement for the data with a different model than 1A3K. 
 
Searches for the remaining units were performed using Phaser (Adams et al 2010) 
and the model of a single tetramer from the Gal-3[N VII-IX] data set as a probe in a 
new query. The search resulted in the discovery of a third tetramer giving a total 
content of 12 molecules arranged as three tetrameric units (TFZ = 92.5, LLG = 
16089) (Fig 15).   
Fig 14. 2Fo-Fc electron density map of Gal-3[N VII-IX] contoured at 1 level. The first 
round of data refinement showed eight monomers in one unit cell and additional positive elec-
tron density (white arrows) suggesting the presence of more molecules. 
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Although at this resolution side chains are poorly defined, the characteristic jelly-roll 
folding of galectins was clearly observed (Fig 16a). Furthermore, the active site was 
Fig 15. 2Fo-Fc electron density map of Gal-3[N VII-IX] contoured at 1 level. New rounds 
of manual building and refinement asserted the presence of twelve molecules in the unit cell. 
 
Fig 16. Crystal structure of Gal-3[N VII-IX]. The protein preserves the jelly-roll folding 
characteristic of galectins (a), and all the key contacts for -galactoside binding (b). 
H-bonds 
water 
CH/ 
lactose 
a b 
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clear enough to show the hydrogen bond contacts of lactose with Arg162, His158 
and Asn160, and the carbohydrate- interactions with Trp181, as well as the inter-
actions with waters (Fig 16b).  
 
Following these preliminary results, optimization screening conditions were pre-
pared to improve crystals and data quality. These crystals were also taken in a dry-
shipping Dewar to the light source line XALOC (ALBA synchrotron, Cerdanyola 
del Vallès, Spain), and they diffracted to 2.2 Å resolution (Fig 17). Data were inte-
grated with XDS (Kabsch 2010) and a local scaling was applied to reduce systematic 
errors with the CCP4 suite (see Materials and Methods). Details on the X-ray data 
collection are in Table 1. 
 
 
The structure of this high-resolution crystal was solved applying differential Fourier 
techniques, taking the dodecamer model of Gal-3[N VII-IX] at low resolution as an 
initial model for refinement. With this model and after a first round of refinement 
with Phenix (Adams et al 2010), the Rwork and Rfree factors lowered to reasonable 
values of 0.263 and 0.314, respectively. A first look shows that every component of 
the dodecamer conserve the jelly-roll topology of two -sheets made of antiparallel 
strands (S1-S6; F1-F5). 
Fig 17. Diffraction pattern for the high resolution crystals. The X-ray diffraction image is 
at  = 76º with a resolution ring at 2.2 Å. 
2.2 Å 
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TABLE 1. X-RAY DATA COLLECTION FOR GAL-3[N VII-IX] 
Beamline BL13-XALOC (ALBA) 
Wavelength (Å) 0.9794 
Space group P212121 
Unit cell parameters (Å) a = 93.85, b = 98.19, c = 237.81 
Resolution range (Å)* 49.10 – 2.20 (2.32 – 2.20) 
No. of observations 1012467 (147079) 
No. of unique reflections 112248 (16179) 
Multiplicity 9.0 (9.1) 
Completeness (%) 100 (100) 
Mean I/(I) 11.7 (1.8) 
Molecules per asymmetric unit [VM (Å3Da-1)] 12  ( 2.15) 
Rmergea 0.134 (1.233) 
Rmeasb 0.142 (1.308) 
CC1/2c (%) 99.7 (55.8) 
Wilson B-factor 43.25 
aRmerge = ShklSi |Ii(hkl) - <I(hkl)>| / ShklSiIi(hkl), bRmeas= Σhkl (N − 1)−1/2 Σi|Ii(hkl) − <I(hkl)>| / Σhkl 
Σi Ii(hkl), where Ii(hkl) is the intensity measured for the ith reflection and (I(hkl)) is the average 
intensity of all reflections with indices hkl. cCC1/2 is the correlation coefficient between two ran-
dom half datasets (Karplus & Diederichs, 2012). *Values in parentheses are for the highest res-
olution shell. 
 
 
Strong electron density corresponding to ordered parts of the N-terminal tail could 
only be detected in three of the twelve monomers of Gal-3[N VII-IX], most likely 
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Fig 18. 2Fo-Fc electron density maps for two ordered segments of the N-terminal tail contoured 
at 1. (a) Specific characteristics of amino acids such as His and Phe allowed for their unequivocal 
identification in the electron density maps when building the N-LD section. (b) A different region 
was identified as part of the N-PG unit IX and residues preceding the CRD. 
a b 
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due to its flexible nature. For these three monomers, the electron density clearly 
indicated the presence of two different regions of the N-PG rather than two 
alternative conformations of the same segment (Fig 18a/b). To build a model in both 
electron density regions, the sequence available for the Gal-3[N VII-IX] construct 
(Fig 19) was used to accurately assign the sequence in order to identify and fit the 
side-chain amino acids. 
 
Once the dodecamer of Gal-3[N VII-IX] was solved, it was evident that, while many 
biological reports state that Gal-3 oligomerizes through the N-PG, the tetramers in 
this structure are facing each other’s CRDs. The amino acid sequences were 
compared to the electronic densities obtained with the X-diffraction data, and several 
rounds of manual building in Coot (Emsley et al 2010) followed by refinement with 
phenix.refine (Adams et al 2010) allowed to unequivocally assign the two following 
distinct fragments of the N-terminal tail: 
Fig 19. Sequences of Gal-3 full length (Gal-3FL), Gal-3[N VII-IX] and Gal-3 CRD only. The elec-
tronic densities obtained from the X-ray diffraction data were compared with the available sequences 
on the proteins to figure out amino acid accommodation. The letters in light blue mark the N-PG amino 
acids built, Asn4-Pro117 of the N-LD and Ala100-Val116 of section IX and the link between the N-
terminal and C-terminal (black square). 
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(A) in two monomers, residues Asn4 to Pro17 corresponding to the N-LD section 
can be modelled with high confidence due to specific sequence landmarks (Fig 20), 
like the imidazol ring of histidine in position 8 (His8) and the phenyl ring of 
phenylalanine in position 5 (Phe5). Notably, this region at the N-terminal forms a 
double-stranded antiparallel β-sheet stabilized by a hydrogen bonding network 
(Table A). The presence of the additional β-strands, called F0 and F-1, extend the 
β-sheet on the Gal-3 β-sandwich face F1-F5, reducing the flexibility of the N-LD 
amino acids, which then may facilitate their availability for phosphorylation in key 
positions such as Ser6 and Ser12. 
  
Table A. Hydrogen bond interactions stabilizing the N-LD 
  Atom 1                   Atom 2 Distance (Å) 
O Ser12 O  Thr246 2.74 
O Ser12 N    Asp9 2.73 
N  Gly13 O    Tyr247 3.05 
O  Gly13 N    Tyr247 3.04 
N  Ser14 O    Leu7 2.71 
O  Ser14 N    Leu7 2.76 
N  Gly15 O    Ala245 2.76 
N  Asn16 O    Phe5 2.53 
O Ser6 N2 His8 2.52 
Fig 20. Clues for building the N-LD region. The rings formed by His8 and Phe5 are 
indicated with black arrows (left). A specific set of contacts between the C-terminal region 
of the CRD and the N-LD residues reduces the flexibility of the newly constructed section 
(right). 
 
Phe5 
His8 
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Fig 21 shows a stereoscopic view of the newly constructed amino acids in the N-LD  
with residues of the C-terminal CRD stabilizing them. 
 
(B) on the other hand, a continuous electron density was observed near the CRD of 
one monomer (Fig 18b) that allowed us to trace part of the N-PG unit IX and residues 
preceding the CRD (Ala100 – Val 116) (Fig 22).  As can be seen, this region display 
a flexible random-coil-like conformation stabilized by hydrogen bonding between 
backbone atoms of sequencial residues, and additionally by the interaction of Tyr107 
with His217 of a symmetry related neighbour (Table B). 
 
 
 
 
 
*symmetry related residue 
 
Table B. Hydrogen bond interactions stabilizing the N-PG unit IX 
Amino acids in contact Distance (Å) 
N  Ala111 O  Ala103 3.0 
O  Ala111 N  Ala103 2.76 
O Tyr107 N1  His217* 2.89 
BACK TO OUTLINE 
Fig 21. Stereoscopic view of the constructed amino acids Asn4-Pro17. With sticks representation, 
in orange: the amino acids belonging to the previously solved Gal-3 CRD; in yellow: the missing N-
terminal Asn4-Pro17 residues, forming a double-stranded antiparallel  -sheet on the F-face (F0 and 
F-1) . 
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Fig 23 shows a stereoscopic view of the newly constructed amino acids from section 
IX and the first portion of the CRD. 
 
Fig 22. Close-up view around the N-PGregion (Ala100-Val116). Two hydrogen bonds 
between Ala103 and Ala111 stabilize this region. 
BACK TO OUTLINE 
Fig 23. Stereoscopic view of the electron density map around the N-PG region. With sticks represen-
tation, in orange: the amino acids belonging to the previously solved Gal-3 CRD; in yellow: region corre-
sponding to the residues joining the N-terminal CRD and those of section IX of the N-PG. 
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Finally, water and lactose molecules were placed using Coot (Emsley et al 2010) and 
refinement of the final model converged to Rwork = 0.243 and Rfree = 0.284. A 
summary of the final refinement parameters is given in Table 2. Validation of the 
final model was done with the Molprobity software and 96.4% of residues were 
located in favored regions of the Ramachandran plot (Fig 24). 
 
TABLE 2. REFINEMENT STATISTICS FOR GAL-3[N VII-IX] 
Refinement  
Resolution range (Å) 49.50 – 2.20 (2.26 – 2.20) 
Working reflections 106537 (7797) 
Testing reflections 5607 (413) 
Completeness (%) 99.97 
Rwork 0.213 (0.342) 
Rfree 0.264 (0.350) 
  
No. of non-H atoms  
Protein 13566 
Lactose 276 
Sulfate ions 120 
Water 128 
Average B factors (Å2)  
Protein 47.15 
Lactose 31.14 
Sulfate ions 56.26 
Water 34.91 
  
R.m.s. deviations  
Bond lengths (Å) 0.014 
Bond angles (˚) 1.83 
Ramachandran plot statistics  
Favoured (%) 96.4 
Allowed (%) 3.4 
Outliers (%) 0.2 
Values in parentheses are for the highest resolution shell. 
 
With all this structural information, significant progress has been made in the 
structural resolution of human Gal-3 showing pictures for two different regions of 
the N-PG tail. However, reconstruction of the full-length Gal-3 and the truncated 
Gal-3 [N VII-IX] need other biophysical techniques, e.g. SAXS, to provide a more 
complete picture. 
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Fig 24. Ramachandran plot for Gal-3[N VII-IX] 
Asp 178 located in a flexible loop is in a disallowed region. All the other residues were in the 
favored and allowed regions (>98%). 
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Small-Angle X-ray Scattering 
Small-angle X-ray Scattering of Gal-3[N VII-IX] and Gal-3FL were measured using 
synchrotron radiation at the ESRF facilities (Grenoble, France). Solutions of purified 
galectins were prepared at concentrations in the range between 3 and 10 mg.ml-1 for 
Gal-3[N VII-IX] and from 2 to 8 mg.ml-1 for the full-length. To prevent freezing 
damage, the samples were transported at 277 K to the ESRF. The samples’ freezing 
process had a negative effect on protein stability leading eventually to protein pre-
cipitation, particularly at higher concentrations. However, the data collection pos-
sessed an appropriate quality and indicated that Gal-3[N VII-IX] and Gal-3FL are 
monomeric over the concentration range tested.  
 
Curve fitting of the experimental data for Gal-3[N VII-IX] (Fig 25a/b) and for Gal-
3FL (Fig 26a/b) was used to build the corresponding bead models (Fig 25c and Fig 
26c for Gal-3[N VII-IX] and Gal-3FL, respectively) using the ATSAS software pack-
age (Svergun 1992). The calculated molecular weights were 20.98 kDa for Gal-3[N 
VII-IX] and 31.54 kDa for Gal-3FL, in good agreement with the theoretical values. 
Rg and Dmax provide secure information on the nature of the interactions between 
domains and of the total protein size (Putnam et al 2007). Thus, the 3D shapes ob-
tained for Gal-3[N VII-IX] and Gal-3FL corresponded to elongated particles, con-
firming the pair-distance distribution functions (Figs 25b and 26b). 
 
The final structure was modelled and compared with both Gal-3FL model and the 
crystal structure of the solved Gal-3 CRD with PyMol (DeLano 2012) in order to 
observe its distinctive characteristics from the other structures of the same protein. 
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Fig 25. Small-Angle X-ray scattering (a) GNOM curve fitting for a 6 mg.ml-1 Gal-3[N VII-
IX] solution; (b) Pair-distance distribution function for Gal-3[N VII-IX] ; (c) bead model rep-
resentation calculated using the ATSAS package. 
a 
b 
c 
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Fig 26. Small-Angle X-ray scattering (a) GNOM curve fitting for a 2 mg.ml-1 Gal-3FL solution; 
(b) Pair-distance distribution function for Gal-3FL; (c) bead model representation calculated us-
ing the ATSAS package. 
a 
b 
c 
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                                                                                                                                             C-GRP-C 
E. coli expression and protein purification 
 C-GRP-C synthetic cDNA (ATG: biosynthetics, Merzhausen, Germany) with pri-
mers GRPNdeI and GRPXhoI designed from the nucleotide sequence (Sigma-Al-
drich, Missouri, USA) was amplified by PCR. As shown in Fig 27, a PCR product 
of the expected size (426 bp) appeared at the Mg2+ recommended concentration pro-
vided by the manufacturer (Fig 27a). One step PCR subcloning allowed the insertion 
of the C-GRP-C gene into the bacterial plasmid expression vector pET28-PP be-
tween the NdeI and XhoI restriction sites (see Materials and Methods). 
 
E. coli BL21 (DE-3) strain was used for large-scale expression as described in Ma-
terial and Methods. Cell lysates were run on a 12% SDS-PAGE, which showed that 
C-GRP-C (16 kDa M.W., Fig 27b black boxes) was among the other bacterial pro-
Fig 27. Gene and protein expression of C-GRP-C. (a) PCR amplification of C-GRP-C was 
tested in an agarose gel (yellow boxes), the PCR positive control is marked with a black arrow. 
(b) Protein presence in the E. coli lysates was checked by SDS-PAGE. A protein of 16 kDa 
M.W. was spotted (black boxes). Protein purification of C-GRP-C. (c) After purification, 
the presence of the protein was checked by SDS-PAGE. 
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teins. The soluble fraction was loaded onto a nickel charged HiTrap chelating col-
umn followed by incubation and dialysis with 3C-protease to remove the His tag. 
The concentrated fractions’ purity is shown in Fig 27c.  
 
Further purification was carried out through a size exclusion chromatography step 
(Superdex 75). The chromatogram (Fig 28) presents two differentiated peaks, which 
could be an indication of the presence of C-GRP-C oligomers in solution. Both peaks 
were verifyied for purity through an SDS-PAGE (Fig 28, inset). Each fraction was 
tested individually, lanes [9] to [11] and lanes [17] to [20]. 
  
 
In Fig 28, the first elution peak (black arrow) shows a mixture of three different 
molecular species (black boxes). On the other hand, the second elution peak (green 
arrow) shows a very pure C-GRP-C with the expected molecular mass (green box). 
These fractions were treated separately and used for crystallization, SAXS and 
analytical ultracentrifugation experiments. 
 
  
BACK TO OUTLINE 
Fig 28. Purification of C-GRP-C by size exclusion chromatography. The elution profile showed 
two differentiated peaks. The inset shows the analysis by SDS-PAGE of the corresponding fractions 
for both peaks. 
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X-ray diffraction resolution 
For C-GRP, initial attempts to crystallize 
it were not successful. It was clear that a 
well ordered structure of the N-terminal 
could not be attained to enable crystal 
formation. Therefore, as previously per-
formed for His-tagged human GRP, this 
sequence portion was deleted (total of 36 
amino acids) to produce a shortened 
form, in analogy to human GRP-C (Zhou 
et al 2008). Diffracting C-GRP-C crystals 
grew after two weeks (Fig 29). A high-
resolution dataset was collected in the 
XALOC line at the ALBA synchrotron. 
The crystals diffracted to a resolution of 
1.55 Å (Fig 30). The crystals belonged to 
the body-centered orthorhombic space group I212121 with unit cell parameters a = 
38.6, b = 106.9 and c = 114.1 Å. Analysis of the crystal content indicated one mon-
omer in the asymmetric unit, with a Matthews coefficient of 3.57 Å3Da-1, which cor-
responds to a solvent content of 65.52%. The crystal structure was determined at 
Fig 29. C-GRP-C crystal. In this image, a 
single crystal of the protein is located in the 
lower left corner. 
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Fig 30. X-ray diffraction data of C-GRP-C. After a 36 amino acid sequence portion was 
deleted, crystals of the protein diffracted to a resolution of 1.5 Å. 
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1.55 A resolution by molecular replacement using the coordinates of the human hom-
ologue (PDBID: 3BC9; Zhou et al 2008). The final model includes 134 amino acid 
residues, 2 sulphate ions, 3 PEG, 3 ethylene glycol and 104 water molecules in the 
asymmetric unit (Fig 31). The C-GRP-C monomer consists of a single β-sandwich 
domain composed of two antiparallel five-stranded (F1-F5) and six-stranded (S1-
S6) β-sheets which is characteristic of the jelly-roll topology shared by all known 
galectins (Gabius et al 2011; Solís et al 2015). 
 
 
In addition to the sequence similarities between galectins and GRP, significant dis-
similarities can be observed at the residues that form the architecture of the carbohy-
drate-binding site in galectins. The stereochemical quality of the model, with unam-
biguous electron density allowed a clear tracing of this region (Fig 32). This concave 
surface of the β-sheet, comprising residues from β-strands S4-S6, characterizes the 
recognition site for β-galactosides in galectins.  Looking at the sequence signature 
for operative binding in canonical chicken galectins (His45, Asn47, Arg49, Asn58, 
Trp65, Glu68, and Arg70 for CG-2) is turned into Glu86, Lys88, Val90, Asn99, 
Trp106, Glu109 and Ser111 in C-GRP-C. It is evident that only three of seven po-
sitions of the highly conserved binding residues are maintained: Asn99, Trp106 and 
Fig 31. Crystal structure of C-GRP-C. The protein preserves the jelly-roll folding as expected, but 
does not possess the ability to bind -galactosides. The strands of the two β-sheets are labeled, as well 
as a short 310 helix placed between strands F5 and S2. 
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Glu109. In particular, the Trp106 is present in avian GRP but not in human GRP, 
and is the responsible for the carbohydrate- interactions in galectins’ CRD. 
 
 
 
 
The final model has a good geometry with 99.2 % of the residues located in the most 
favored regions of the Ramachandran plot (Fig 33). Summary statistics of the C-
GRP-C geometry obtained for the final model are shown in Table 3.  
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Fig 32. Close-up view of the putative contact site for a β-galactoside in C-GRP-C. Re-
spective residues in C-GRP-C as well as an ethylene glycol molecule are shown in ball-and-
stick mode. Water molecules are depicted as red spheres. The observed electron density map 
2Fo-Fc is contoured at 1.0 σ. 
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TABLE 3. DATA COLLECTION AND REFINEMENT STATISTICS FOR C-GRP-C 
Data collection  
Beamline BL13-XALOC (ALBA) 
Wavelength (Å) 0.9794 
Space group I212121 
Unit cell parameters (Å) a = 38.6, b = 106.9, c = 114.1 
Resolution range (Å) 57.04 - 1.55 (1.63 - 1.55) 
No. of observations 300868 (40181) 
No. of unique reflections 34844 (4882) 
Multiplicity 8.6 (8.2) 
Completeness (%) 99.7 (97.6) 
Mean I/s(I) 12.6 (2.2) 
Molecules per asymmetric unit [VM (Å3Da-1)] 1 molecule (VM= 3.91) 
Rmergea 0.069 (0.977) 
Rmeasb 0.074 (1.043) 
CC1/2c 99.9 % 
Mosaicity 0.20 
Wilson B-factor 21.62 
Refinement  
Rwork/Rfree 0.168 (0.267) / 0.189 (0.30) 
Working reflections 33160 (2285) 
Testing reflections 1593 (101) 
Protein atoms (non H) 1064 
PEG and ethylene glycol 36 
Sulfate ions 10 
Water molecules 102 
Mean B factors (Å2)  
Protein 27.23 
PEG and ethylene glycol 57.45 
Sulfate ions 58.01 
Water molecules 42.42 
rmsd bond lengths (Å) 0.008 
rmsd angles (˚) 1.36 
Ramachandran plot statistics  
Favored (%) 99.2 
Outliers (%) 0 
PDB accession ID 5IT6 
 
aRmerge = ShklSi |Ii(hkl) - <I(hkl)>| / ShklSiIi(hkl), bRmeas= Σhkl (N − 1)−1/2 Σi|Ii(hkl) − <I(hkl)>| / Σhkl 
Σi Ii(hkl), where Ii(hkl) is the intensity measured for the ith reflection and (I(hkl)) is the average 
intensity of all reflections with indices hkl. cCC1/2 is the correlation coefficient between two ran-
dom half datasets (Karplus & Diederichs, 2012). Values in parentheses are for the highest reso-
lution shell 
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Small-Angle X-ray Scattering 
Small-angle X-ray Scattering of C-GRP-C was measured using synchrotron 
radiation at the ESRF facilities (Grenoble, France). Solutions of purified C-GRP-C 
used in the SAXS measurements were prepared at concentrations in the range be-
tween 2 and 8 mg·ml-1. To prevent freezing damage, the samples were transported 
at 277 K to the ESRF. The estimated radius of gyration using the Guinier approxi-
mation was Rg = 20 Å. There was no noticeable dependence of the radius of gyration 
on protein concentration. Curve fitting of the experimental data (Fig 34a) and final 
bead model (Fig 34b) was performed using the ATSAS software package (Pe-
toukhov et al 2012). The calculated molecular weight of C-GRP-C was 16.2 kDa, so 
this speaks of the behavior of C-GRP-C as a monomer in solution even at 8.0 mg·ml-
1. The value of Rg obtained from the GNOM fit was 18.3 ± 0.7 Å, in good agreement 
with the value obtained by the Guinier approximation, and a Dmax = 54 Å. An addi-
tional experiment, to prove the presence of monomeric species, was provided by 
AUC. 
BACK TO OUTLINE 
Fig 33. Ramachandran plot for C-GRP-C 
All the other residues were located in the favored and allowed regions. 
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Fig 34. Small-Angle X-ray Scattering of C-GRP-C. The SAXS values for this protein account for 
the presence of a monomer in solution. (a) Experimental data (b) final bead model obtained from the 
data using the ATSAS package. 
a) 
b) 
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Analytical ultracentrifugation 
Analytical ultracentrifugation was run using C-GRP-C samples at concentrations of 
0.2, 1 and 2 mg·ml-1. Differential sedimentation coefficients were calculated by least 
squares boundary modeling of the experimental data using the c(s) method. C-GRP-
C was monomeric over the full concentration range tested. The calculated 
sedimentation coefficient was 1.161 ± 0.006 S with a frictional ratio of 1.30 (Fig 
35a). Afterwards, it was decided to test the full-length protein (C-GRP) in order to 
assess whether the non-CRD (36 amino acids deletion) portion could participate in 
the protein’s oligomerization in solution, as it happens with Gal-3. As for the 
shortened version, the calculated sedimentation coefficient was similar, with a value 
of 1.137 ± 0.008 S with a frictional ratio of 1.52 (Fig 35b).  
 
Thus, the differential coefficient distribution c(s) curves suggest that both C-GRP-C 
and C-GRP are monomeric in solution, with apparent molecular weights of 16.5 kDa 
and 19 kDa, respectively. No oligomer formation was seen under all conditions 
tested. 
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Fig 35. Analytical ultracentrifugation C-GRP-C and C-GRP. In the experiments of sedimentation ve-
locity at 2.0 mg.ml-1, both (a) C-GRP-C and (b) the full-length protein (C-GRP), are predominantly mon-
omeric in solution, as well as no sign of oligomer formation throughout the entire experiment. 
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DISCUSSION 
 
Galectins are -galactoside-binding proteins involved in the regulation of several 
cellular processes, both physiological and pathological. Galectins have been identi-
fied as important targets in cancer, angiogenesis and tumor metastasis, both as mark-
ers and as inhibitable molecules to prevent development and progression of cancer 
(Thijssen et al 2013). Because they promote at the same time tumor cells survival 
and neutrophile apoptosis in a location-dependent manner, galectin regulators, as a 
therapy strategy, will importantly contribute to other treatments in cancer such as 
VEGFR inhibition (Rabinovich et al 2014; Compagno et al 2014). Moreover, besides 
their participation in cancer, galectins mediate, in a carbohydrate-dependent manner, 
bacterial adhesion to host cells and inflammatory processes, e.g. rheumatoid arthritis, 
preeclampsia and other obstetric syndromes, etc. (Vasta et al 2012; Than et al 2012; 
Thiemann and Baum 2016). 
 
                                                                                                 GAL-3[N VII-IX] AND GAL-3FL 
A characteristic of some galectin types is that they are tissue-specific, like Gal-7 and 
-10, while others are ubiquitous like Gal-1, -3 and -9 (Cooper et al 2002). Therefore, 
the latter are the most studied among the galectin family members. Both full struc-
tures of Gal-1 and -9 have been solved (López-Lucendo et al 2004; Solís et al 2010), 
as well as a significant number of structures of the CRD domain of Gal-3 (Seetha-
raman et al 1998). 
 
However, the lack of a structure for Gal-3 poses a limitation for the development of 
pharmaceutical effectors for clinical aplication against the aforementioned diseases. 
Indeed, being the only chimera type galectin, Gal-3 has eluded full structural resolu-
tion since the first time the CRD domain of this protein was described nineteen years 
ago. While Gal-3 has been widely reported in cancer biology studies to execute its 
functions by multimerization (Rabinovich et al 2002a; Thiemann and Baum 2016), 
the only available crystal structures of the Gal-3 CRD do not show how this protein 
interacts to form such multimers. Moreover, while the CRD alone has an overall 
globular shape, it is unknown what shape does Gal-3 adopt with the elongated N-
terminal flexible domain. 
 
In this work, the structural resolution of Gal-3 was undertaken from a protein engi-
neering approach. Several constructs of distinct Gal-3 deletion variants were ob-
tained by recombinant techniques with different degrees of tail truncation, mimick-
ing the naturally occurring products by cleavage the N-terminal poly-proline/glycine 
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(N-PG) tail with matrix metalloproteinases (MMPs) (Kopitz et al 2014). The rela-
tionship between Gal-3 and MMPs is important on both sides, as well as for many 
other extracellular proteins involved in ECM remodeling, angiogenesis, invasion and 
metastasis. For instance, shortening the N-PG with MMP-2 and -9 renders Gal-3 
unable to activate neutrophiles and reduces its angiogenic potency (Funasaka et al 
2014a; Machado et al 2014). On the other hand, MMP-9 deficiency leads to Gal-3 
accumulation in hypertrophic chondrocytes, impeding normal bone formation. In re-
turn, extracellular Gal-3 regulates MMP-1 and -9 expression at the transcriptional 
level, and induces MMP-9 secretion in a metastatic melanoma cell line (Gao, Liu et 
al 2017).  
 
A particular construct, consisting of three of the nine PG repeats (seven to nine) plus 
the N-terminal lead peptide (N-LD) and the CRD, namely Gal-3[N VII-IX], crystal-
lized with high reproducibility, and diffracted to 2.2 Å (see Results). The [N VII-IX] 
elongation in this Gal-3 construct changed the way the protein molecules build up, 
in a dodecamer, in the crystal lattice. 
 
The Gal-3[N VII-IX] crystal structure showed new structural features, giving a com-
plete picture of the multimerization mode. According to Gao, Liu et al (2017), pro-
tease-mediated Gal-3 cleavage generates both the intact CRD and with N-terminal 
peptides of varying lengths that retain lectin binding activity but lose multivalence 
in every instance that the N-PG is incomplete. In apparent contradiction to this, Gal-
3[N VII-IX] crystal presented twelve molecules in the unit cell, specifically in the 
form of three tetramers (Fig 36). It stands out that oligomerization is mediated by 
interactions among subunits through the C-terminal end, being the three tetramers 
facing each other’s CRD. This type of oligomerization in Gal-3 via self-association 
of the CRD is called a C-type self-association (Gao, Liu et al 2017).  
 
As it is depicted in Fig 36 (tetramers marked using different colors), for each te-
tramer the lactose ligands bound to the carbohydrate-binding sites are in close prox-
imity to each other, while the N-terminals (drawn in red) are on the opposite side. In 
two monomers, the modelled N-terminal corresponding to residues Asn4-Pro17 has 
a -sheet structure (Fig 36, red in yellow) conforming two β-strands F0 and F-1, 
stabilized in its place by a specific set of contacts between amino acids of the N-LD 
and the F1 strand of the CRD. In a third monomer, a few residues of the Pro/Gly-
rich repeating unit IX and residues preceding the CRD, Ala100-Val116 , were built 
with a flexible random-coil-like conformation (Fig 36, red in blue) stabilized by a 
hydrogen bond network (see Results). 
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C-type self-association of Gal-3 has been shown in FRET, using Gal-3 labeled at the 
C-terminal (Nieminem et al 2007), in NMR experiments (Ippel et al 2016), and when 
Gal-3 is incubated with asialofetuin as well as with multivalent glycoconjugates lo-
cated in the same cell membrane (Lepur et al 2012; Vasta et al 2012; Gao, Liu et al 
2017).   
 
Considering this, it is very likely that the C-type self-association observed in the Gal-
3[N VII-IX] crystal structure may be at least partially mediated by the presence of 
close contacts between the lactose ligands (Fig 37, purple arrow), that imitate a clus-
ter in which Gal-3 oligomerizes in presence of its natural ligands. However, in every 
instance, the N-PG has to be present for oligomerization to occur. This may also 
explain the differing results with other experiments (Gao, Liu et al 2017) in which 
truncated forms of Gal-3 with the N-PG do not oligomerize in absence of ligands. In 
Fig 37 (black arrow) can also be seen two sulfate molecules, apparently stabilizing 
the tetramer by replacing water molecules (Seetharaman et al 1998), a feature that is 
most likely a packing artifact since computational studies show how accommodation 
of the sulfate group will be disfavored by steric hindrance. 
 
Fig 36. Crystal packing of Gal-3[N VII-IX] within the asymmetric unit. The ribbon representation 
shows three tetramers with the characteristic jelly-roll motif, with the CRDs facing each other. Bound 
lactose molecules at the CRD are depicted in stick representation (pink). The constructed sections of 
the [N VII-IX] are drawn in red. 
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A comparison of the monomers, and particularly of the protein surfaces at the N-PG 
extension (Fig 38), allows to clearly identify the start and end points of the amino 
acid sequence for the constructed N-PG with, unexpectedly, a well-defined structure. 
The last Pro/Gly-rich repeating unit is located on the opposite side of the CRD. In-
terestingly, the double-stranded antiparallel β-sheet formed by residues Asn4-Pro17 
(Fig 38, left) extends the antiparallel β-sheet on the F-face of the Gal-3 structure, 
thus reducing flexibility of the N-terminal. 
 
This provides that residues implied in the phosphorylation of Gal-3 (i.e., Ser6 and 
Ser12) are located in a defined region, which may facilitate the process, and are far 
away from the carbohydrate-binding pocket that mediates glycan-dependent func-
tions (see below). The other constructed N-PG portion, Ala100-Val116 (Fig 38, 
right), comprises residues that overlap with the CRD domain and contains a cleav-
age site for MMPs at the Pro112/Leu113 bond, leaving a zone of six amino acids 
that conform the link between the C- and N-terminal domains. The rest of this region, 
comprising residues Ala100-Pro106 from the IX repeat extends the structure away 
from the S1 -sheet of the C-terminal CRD. 
 
Fig 37. Features in the crystal structure of Gal-3[N VII-IX]. Lactose ligands at the 
CRDs are arranged in a network with very close contacts, stabilized with the presence 
of sulfate ions. 
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Superposition of both monomers (Fig 39) shows a well-fitting of the CRD domains   
(r.m.s.d. 0.8 Å for C-atoms), and suggests the way to connect both ends, i.e. the 
entire 22-residue segment of the repeating units VII and VIII and the connection with 
the N-terminal, since lack of electron density prevents the modelling of this part of 
the protein. To do a more detailed analysis of the structure and to provide a complete 
picture of Gal-3, experimental SAXS data in solution was used to determine the 
global architecture of Gal-3, with samples from both Gal-3[N VII-IX] and Gal-3FL. 
Fig 38. Isolated monomers of Gal-3[N VII-IX] with two different N-PG sections. The amino 
acids newly constructed in the N-LD section (left) seem to ‘come back’ from the elongated structure 
of section IX of the N-PG (right). 
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As it is known that Gal-3 multimerization is initiated at a certain threshold concen-
tration (nucleation) (Lepur et al 2012), is ligand-dependent (Funasaka et al 2014b) 
and this self-association can cause aggregation and/or precipitation, size exclusion 
chromatography with buffer exchange was successfully applied to obtain clear solu-
tions of both Gal-3[N VII-IX] and Gal-3FL for testing in a SAXS beamline (BM29 
line, ESRF). 
 
SAXS data indicated that both Gal-3[N VII-IX] and Gal-3FL are monomeric at con-
centrations below 8 mg·ml-1 based on the maximum particle dimension (Dmax) and 
Guinier plots (see Results). At concentrations above 8 mg·ml-1, Gal-3[N VII-IX] 
started to aggregate and data could not be analyzed. The full-length protein showed 
even higher propensity to aggregation. Molecular envelopes were generated ab initio 
(Svergun 1999), selected, combined and filtered to produce an averaged model in 
which both shapes corresponded to elongated particles (Figs 25b/26b from Results). 
 
Based on the surface envelopes calculated from SAXS and with the available crystal 
structure of Gal-3 [N VII-IX], it can be modelled, inside the empty surface area, the 
extended segment corresponding to the VII and VIII repeats missing from the crystal 
structure. First, for this connecting segment the models generated are analyzed by 
secondary structure prediction servers, like RaptorX and I-TASSER. The predicted 
structure was an almost linear and long polypeptide chain with the N-terminal point-
ing in the opposite direction of the CRD. Then, Coot (Emsley et al 2010) was used 
Fig 39. The N-PG structure. Overlapped 
representation of all the constructed amino acids 
from the X-ray diffraction data. 
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to build the model, taking into account the biological properties of Gal-3, i.e. the 
positions of two serine residues as acceptors for phosphorylation (Ser6 and Ser12) 
and the seven cleavage sites for MMPs and PSA (Kopitz et al 2014). The first re-
quirement is fulfilled since Ser6 and 12 are correctly positioned in the double-
stranded antiparallel β-sheet (F0 and F-1) in a conformation that favours phosphor-
ylation (see below). Secondly, sites for protease cleavage must be solvent exposed 
(Gly31/Ala32, Ala62/Tyr62, Pro75/Gly76, Pro89/Ser90, Pro101/Ala102, 
Tyr106/Gly107 and Pro112/Leu113). With this in mind, the corresponding residues 
were accommodated inside the surface in a closed conformation with an elongated 
shape and the molecule was submitted to molecular dynamics simulations. The final 
models are shown in Fig 40. 
 
 
Fig 40. Electrostatic surface representation of crystalline Gal-3 CRD, and SAXS-resolved 
Gal-3[N VII-IX] and Gal-3FL. (a) The crystal structure for Gal-3 CRD (yellow) presents a com-
pact shape. (b) SAXS data for Gal-3[N VII-IX] (magenta) shows a structure where the [N VII-
IX] was built (yellow inside magenta), and that supports the idea of the N-PG not adopting a 
random-coil conformation. (c) Gal-3FL (blue) grows further away from the globular shape, where 
amino acids from sections I to VI would accommodate. 
b 
c 
a 
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One of the most important post-translational modifications of Gal-3, that has the po-
tential to alter important biological functions, is the phosphorylation of Ser6 (Fig 
41). Ser12 and several Tyr residues in the protein are susceptible to be phosphory-
lated as well. However, it is Ser6 phosphorylation/dephosphorylation what has a key 
role in regulating, for instance, Gal-3 TRAIL-induced apoptosis, cell distribution, 
and binding ability (Gao, Liu et al 2017). In the Gal-3[N VII-IX] structure modelled 
with both X-ray crystallography and SAXS data, this Ser6 residue is readily availa-
ble in the surface of a pocket where kinases may bind and activate Gal-3. Even for 
the full-length Gal-3, the position of the Ser6 is likely to remain as it is. 
 
 
 
More specifically, Gal-3 Ser6 phosphorylation by Protein Kinase I (formerly known 
as Casein Kinase I, CKI) regulates Gal-3 function producing the only nuclear export 
fraction that can be exported from the nucleus to the cytoplasm and protect cells from 
mitochondrial membrane permeabilization-mediated apoptosis. Unphosphorylated 
Fig 41. Ser6 phosphorylation site. Modelling of the Gal-3[N VII-IX] with X-ray dif-
fraction and SAXS data allows to discover that the Gal-3 major phosphorylation site is 
readily available in the molecular surface. 
Ser6 
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mutant Gal-3 accumulates in the nucleus and doesn’t exhibit its anti-apoptotic func-
tion (Nakahara et al 2006; Gao, Liu et al 2017). A closer look to the model (Fig 42) 
shows that the pocket with the Ser6 in Gal-3[N VII-IX] forms a groove perfectly 
complementary in shape with the active site of the CKI (Arg128, PDBID: 5MQV; 
Halekotte et al 2017) that allows this kinase an easy access to the binding site pocket. 
This means that even MMP-processed Gal-3 would be capable of exiting the nucleus 
to aid cells escape the cell death program. 
 
 
The anti-apoptotic function of exported Ser6-phosphorylated Gal-3 works in favor 
of cancerous cells, which overproduce Gal-3 and this in turn helps them escape cell 
death. Prevention of phosphorylation will prevent its nuclear export, but no specific 
inhibitors for this have been designed. Gal-3 structure deserves further investigation 
in order to understand its functions, mechanisms of action, and to develop a library 
of structures that may serve as agonists or antagonists for the protein’s regulation in 
pathological processes. This new structure with the N-terminal section that contains 
the phosphorylation site sets the path for development of further research in aid of 
the existing therapies. In all, the success for the first time on the structural resolution 
of a truncated variant that contains the chimeric module of Gal-3, although short-
ened, marks the start point for Gal-3FL structural elucidation. 
Ser6 
 
Gal-3[N VII-IX] 
Protein Kinase I 
Fig 42. Protein Kinase I binding to Gal-3. The tertiary structure of Gal-3[N VII-IX] forms a pocket 
that leaves a major phosphorylation site available for protein-protein interaction with Gal-3’s natural 
kinase in processes of cytoplasm to nucleus translocation, CKI. 
CKI active site Arg128 
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                                                                                                                                             C-GRP-C 
On to C-GRP-C, the gene for the Galectin-Related Protein is present exclusively in 
vertebrates, with high-level sequence conservation and similar chromosomal posi-
tioning when, in contrast, occurrence of canonical galectins is known to also happen 
in organisms such as fungi, nematodes and insects. Therefore, the GRP gene ought 
not to be a recent acquisition by duplication of an ancestral gene within a distinct 
species but an integral component of the vertebrate genome. This sequence conser-
vation among various species implies a very strong positive selection, as generally 
seen for genes encoding proteins with multiple aspects involved in critical interac-
tions, say with itself, other proteins and/or specific ligands (Cooper 2002).  
 
Biochemical and structural characterization of GRP, a product from a gene under 
strong positive selection, is a pre-requisite for functional characterization and net-
work monitoring of the whole galectin family (García, Flores-Ibarra, Michalak et al 
2016). Because this protein does not bind -galactosides, it is not possible to classify 
it under any galectin type, i.e. proto, tandem or chimera. Prototype and tandem-re-
peat galectins normally form homo- and heterodimers, and in human GRP-C crys-
tals, aggregation into dimers and tetramers has been observed (Zhou et al 2008). In 
contrast, several experiments were performed on C-GRP-C and the protein was al-
ways a monomer.  
 
The crystal structure of C-GRP-C, solved at 1.55 Å resolution, revealed its mono-
meric nature. As expected by similarities in the amino acid sequence with galectins, 
C-GRP-C conserves the jelly-roll fold (Fig 43a), formed by a sandwich of antipar-
allel strands, F1-F5 in one face, S1-S6 in the other face, and a 310 helix connecting 
both sides. However, the sequence signature at the canonical binding site, located in 
strands S4-S6 in galectins, drastically changes, affecting the ability of C-GRP-C to 
bind -galactosides. A peculiar feature of C-GRP-C at the central position of the 
CRD is the presence of a Trp106 residue, which is the responsible for the carbohy-
drate- interactions with the B-face of galactose in galectins (Fig 32 from Results). 
Birds, fish and amphibians have a Trp in this position, whereas mammals consist-
ently present a substitution by Arg/Lys. However, this CH- interaction, as funda-
mental as it is for binding galactose moieties in galectins, still fails to bind these type 
of carbohydrate binding in C-GRP-C. 
 
Fig 43b shows a comparative view of the C-GRP-C structure with a canonical 
chicken galectin, CG-2. The sequence signature for binding in CG-2 (His45, Asn47, 
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Arg49, Asn58, Trp65, Glu68 and Arg70) is turned out into Glu86, Lys88, Val90, 
Asn99, Trp106, Glu109 and Ser111 in C-GRP-C: only three out of seven positions 
are thus maintained. Furthermore, Val90, Glu86 and, especially, Lys88, are impair-
ing the set of contacts for the 4′, 6′-hydroxyls of galactose moieties. In particular, it 
is the Lys88 (in yellow, Fig 43b) that protrudes to an extent that disfavors a com-
fortable fit for lactose, so that not even the presence of Trp106 can compensate for 
this distorsion (García, Flores-Ibarra, Michalak et al 2016).  
 
 
Moreover, the low root-mean-square deviations (rmsd) for C atoms, with values 
ranging from 1.07 Å to 1.54 Å, between members of the chicken galectin family: 
CG-1A (1.42 Å), CG-1B (1.54 Å), CG-2 (1.33 Å) and CG-8N (1.07 Å) underscore 
the close relationship. The superposition of the C-GRP-C structure with that of the 
listed canonical CGs, however, disclosed notable differences in several regions in-
volving loops between adjacent -strands at the concave face of the CRD pocket. In 
detail, the S3-S4 loop, which connects antiparallel -strands F4-F5, is five residues 
longer in C-GRP-C and CG-8N than in prototype CGs, for whom (CG-1A and -1B) 
the S4-S5 loop is extended (Fig 44).  
F1 
F2 
F3 
F4 
F5 
S1 
S2 S3 
S4 
S5 
S6 
1 
Fig 43. Overall crystal structure of C-GRP-C. (a) The protein maintains the jelly-roll topology typ-
ical of the galectin family. (b) Superposition of a canonical chicken galectin (CG-2) and C-GRP-C. 
Sugar binding residues of CG-2 (purple) and those of equivalent positions in C-GRP-C (cyan) are 
shown in stick mode. 
W65 
W106 
H45 
E86 
E68 
E109 
R70 S111 
R49 
V90 
N47 
K88 
Lac 
C-GRP-C 
C-Gal-2 
2.7 
2.8 
3.1 
N58 
N99 
a b 
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Then it may be that deviations in the C-GRP-C amino acid sequence account for the 
lack of -galactoside-binding by this protein, although, it is of note that deviations 
in position of the signature glycan-binding sequence do not necessarily mean that a 
member of the galectin family will loose its glycan binding activity. Thus, congerin 
P, a galectin from peritoneal cells of the conger eel (Watanabe et al 2012), and the 
Coprinus cinerea galectin CGL3 (Wälti et al 2008b) have operative binding despite 
similar alterations to C-GRP-C. 
 
Consequently, the absence of key amino acids at the CRD binding site could not be 
the only reason for C-GRP-C distinct behavior. A look at the electrostatic surface of 
both C-GRP-C and CG-2 (Fig 45) shows the prominent Lys88, along with a highly 
acidic surface and the absence of a tunnel-like cavity, present in galectins, that could 
reduce the probability to host galactose moieties. Changes in amino acids that are far 
from the carbohydrate-binding site have been seen in Gal-8 to impair glycan-binding 
ability (Ruiz et al 2014). Additionally, the specific location of GRP in bone marrow 
cells might be indicative for the different biological functions of C-GRP in contrast 
to galectins (Cooper 2002). Altogether, the present results on the C-GRP-C structure 
highlight all the changes present in a Galectin-Related Protein in comparison to the 
rest of the proteins from the galectin family. 
 
BACK TO OUTLINE 
Fig 44. Structural superposition of C-GRP-C (yellow) with the canonical CGs. CG-1A (cyan; 
1QMJ), CG-1B (purple; 3DUI), CG-2 (green; 2YMZ) and CG-8N (orange; 4WVW), highlighting the 
major structural differences in two regions involving connecting loops at the concave face of the CRD 
pocket. 
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Finally, as C-GRP-C, in analogy to human GRP, was engineered to produce a short-
ened and crystallizable form, a series of biophysical experiments were also con-
ducted to determine if the structure of the engineered variant resembles the entire 
full-length protein. The monomer presence was independently confirmed by SAXS 
for C-GRP-C. Sedimentation velocity experiments demonstrated that C-GRP and the 
shortened C-GRP-C maintained the same monomeric status (see Results). SAXS 
modelling was used to obtain a three-dimensional bead model of a monomer with a 
maximum dimension of 48.2 ± 2.3 Å and a molecular mass of 16.2 ± 1.6 kDa that is 
in good concordance with the C-GRP-C structure (Fig 46). Furthermore, cell-bind-
ing capacity assays showed very similar reactivity of the physiological and shortened 
Fig 45. Electrostatic surface potential maps comparison of C-GRP-C (a) with CG-2 
(b) contoured from -10 kT/e (red) to +10 kT/e (blue). The surface of C-GRP-C is highly 
negative owing to the surface distribution of acidic residues (red) and the absence of a tun-
nel-like cavity present in canonical galectins, which accomodates the galactose moieties, is 
really evident. 
a 
b 
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form of C-GRP. These data preclude any influence of the non-CRD portion on bind-
ing capacity. 
 
 
Sequence conservation at a high level, as seen for GRP genes in vertebrates, is a sign 
for the development of a distinct function at the canonical lectin activity’s expense 
(García, Flores-Ibarra, Michalak et al 2016). This structure takes another step 
towards the entire galectin family fingerprinting, and its crystal structure results 
fundamental for characterization of GRP potential physiological ligands. 
 
  
BACK TO OUTLINE 
Fig 46. Averaged bead model of SAXS-resolved C-GRP-C in comparison with C-
GRP-C crystal structure electrostatic surface. In all, the statistical model obtained by 
SAXS and the electrostatic surface of the protein’s crystal appear to have a good 
agreement both in shape and size. 
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CONCLUSIONS 
 
1. Gal-3[N VII-IX] crystallographic structure, the first one solved for this protein 
with a section of the N-PG domain, provides a key starting point for the comple-
tion of Gal-3FL structure. 
 
2. Gal-3[N VII-IX] crystallographic structure establishes the molecular basis for 
the study of the distinct behaviour of Gal-3 with and without its N-terminal do-
main. 
 
3. Gal-3[N VII-IX] structure shows that a key residue of Gal-3 post-translational 
modifications, i.e. Ser6 phosphorylation, accommodates in a readily accessible 
position for binding other effector molecules, such as Gal-3 natural kinase, CKI. 
 
4. Gal-3[N VII-IX] and Gal-3FL SAXS structure clearly shows the deviation of Gal-
3 CRD globular structure into an elongated form, where the crystallographic 
structure fits well. 
 
5. C-GRP-C crystallographic structure shows that avian GRP conserves the jelly-
roll folding adopted by all galectins and, as previously shown by DNA sequence, 
presents a Trp residue (not present in human GRP) in the same position as the 
Trp in galectins that interacts with the galactose ring. 
 
6. C-GRP-C, as human GRP, does not bind -galactosides, and the crystallographic 
structure shows the absence of other key residues for galectins’ glycan binding, 
and the presence of a protruding Lys88, accounting for the lack of C-GRP-C 
binding canonical galectin ligands. 
 
7. The highly acidic surface of GRP, and its localization in bone marrow cells, 
points to a different natural ligand and/or binding site for this protein. 
 
8. C-GRP-C and C-GRP present themselves in the form of monomers, both in crys-
tal form and in solution, corroborated by SAXS and AUC, much as prototypical 
galectins.
BACK TO OUTLINE 
87 
 
 
CONCLUSIONES  
 
1. La estructura cristalográfica de Gal-3[N VII-IX], la primera resuelta para esta 
proteína con una sección del dominio N-PG, proporciona un punto de inicio para 
la resolución estructural de la proteína completa Gal-3FL. 
 
2. La estructura cristalográfica de Gal-3[N VII-IX] establece la base molecular para 
el estudio del comportamiento distintivo de Gal-3 con y sin el dominio N-termi-
nal. 
  
3. La estructura de Gal-3[N VII-IX] muestra que un residuo clave en las modifica-
ciones postraduccionales de Gal-3, esto es, la fosforilación de Ser6, se posiciona 
en una región accesible para la unión de moléculas efectoras, tal como la quinasa 
natural de Gal-3, CKI. 
 
4. Las estructuras resueltas por SAXS de Gal-3[N VII-IX] y Gal-3FL muestran cla-
ramente la desviación de la estructura globular del CRD de Gal-3, con una forma 
alargada donde la estructura cristalográfica se acomoda fácilmente. 
 
5. La estructura cristalográfica de la C-GRP-C muestra que GRP en aves conserva 
el plegamiento jelly-roll adoptada por todas las galectinas y que, como se conocía 
por la secuencia de DNA, presenta un residuo de Trp (ausente en GRP humana) 
en la misma posición que el Trp en galectinas que interactúa con el anillo galac-
tósido. 
 
6. La C-GRP-C, como la GRP humana, no une -galactósidos, y la estructura cris-
talográfica muestra la ausencia de residuos clave para la unión galectina-glicano 
y la presencia de una Lys88, lo que es determinante en la ausencia de afinidad 
de C-GRP-C para unir ligandos canónicos de galectinas. 
 
7. La alta presencia de residuos ácidos en la superficie de la GRP, así como su 
localización en células de la médula ósea, apunta a un ligando natural y/o a un 
sitio de unión diferentes para esta proteína. 
 
8. C-GRP-C y C-GPR se presentan como monómeros, tanto en cristal como en so-
lución, como fue corroborado por SAXS y AUC, una característica de las galec-
tinas prototípicas.  
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